

Namibia Country Operational Plan FY 2018



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Summary of Planned Funding by Agency and Funding Source							
	ı	Funding Source				Total All	
						Funding	
A				Funding	Applied	Sources and	
Agency	GAP	GHP-State	GHP-USAID	Source Total	Pipeline	Applied	
						Pipeline	
						Amount	
State		176,204		176,204	405,609	581,813	
USAID		29,764,926	0	29,764,926	2,492,722	32,257,648	
PC		1,131,953		1,131,953	261,047	1,393,000	
HHS/CDC	1,487,500	35,569,039		37,056,539	0	37,056,539	
HHS/HRSA		200,000		200,000	0	200,000	
State/AF		36,667		36,667	63,333	100,000	
Total	1,487,500	66,878,789	0	68,366,289	3,222,711	71,589,000	

Summary of Planned Funding by Budget Code and Agency

	Agency							
Budget Code	State	HHS/CDC	HHS/HRSA	PC	State/AF	State/SGAC	USAID	Total
CIRC		5,260,391	0	0	0		3,822,271	9,082,662
НВНС		2,095,234	0	0	0		147,297	2,242,531
HKID		0	0	25,641	0	0	4,431,582	4,457,223
HLAB		488,296	0	0	0		0	488,296
HMBL		0	0	0	0		0	0
HMIN		0	0	0	0		0	0
HTXD		0	0	0	0		461,404	461,404
HTXS	7,517	11,989,184	200,000	0	36,667		10,438,096	22,671,464
HVAB		1,158,343	0	0	0		1,680,000	2,838,343
HVCT		1,883,645	0	0	0		1,448,520	3,332,165
HVMS	161,170	3,134,735		1,003,747			1,129,868	5,429,520
HVOP	7,517	3,138,778		102,565	0		1,344,852	



	176,204	37,056,539	200,000	1,131,953	36,667	0	29,764,926	68,366,289
PDTX		1,910,478	0	0	0		960,365	2,870,843
PDCS		756,600	0	0	0		105,852	862,452
OHSS		1,137,757	0	0	0		570,152	1,707,909
МТСТ		631,538	0	0	0		7,657	639,195
IDUP		0	0	0	0		0	0
HVTB		1,463,785	0	0	0		2,088,698	3,552,483
HVSI		2,007,775	0	0	0		1,128,312	3,136,087



Technical Areas

Technical Area Summary

Technical Area: Care

Toomingar 7 in Gario				
Budget Code	Budget Code Planned Amount			
нвнс	1,228,040			
HKID	4,406,535			
HVTB	3,148,821			
PDCS	241,975			
Total Technical Area Planned Funding:	9,025,371			

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	400,000
HVSI	2,453,200
OHSS	1,508,000
Total Technical Area Planned Funding:	4,361,200

Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	8,985,659
HMBL	О
HMIN	0
HVAB	2,827,500
нуст	2,583,800
HVOP	4,532,602
IDUP	0
мтст	362,481
Total Technical Area Planned Funding:	19,292,042



Technical Area: Treatment

Budget Code	Budget Code Planned Amount
HTXD	461,404
HTXS	20,077,809
PDTX	1,868,594
Total Technical Area Planned Funding:	22,407,807



Technical Area Summary Indicators and Targets

Indicator Number	Label	2020
	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	95 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	47,281
	Number of new ANC and L&D clients	49,770
	By Age (Denominator): 10-14	3
	By Age (Denominator): <15-19	7,357
	By Age (Denominator): 20-24	14,021
PMTCT_STAT_DSD	By Age (Denominator): 50+	15
61_61.11_565	By Number of known positives: 15-19	93
	By Number of known positives: 20-24	640
	By Number of known positives: 50+	2
	By Number of new positives: 10-14	1
	By Number of new positives: 15-19	259
	By Number of new positives: 20-24	503
	By Number of new negative: 10-14	2
	By Number of new negative: 15-19	6,730
	By Number of new negative: 20-24	12,091
	By Age (Numerator): 10-14	3
	By Age (Numerator): 15-19	7,074
	By Age (Numerator): 20-24	13,215

Page 6 of 325



	By Age (Numerator): 50+	2
	PMTCT_STAT_D_DSD_Age_Sex	44.700
	25-29, Female	11,720
	PMTCT_STAT_D_DSD_Age_Sex	0.007
	30-34, Female	9,097
	PMTCT_STAT_D_DSD_Age_Sex	5.000
	35-39, Female	5,382
	PMTCT_STAT_D_DSD_Age_Sex	
	40-49, Female	2,175
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 25-29, Female,	1,387
	Known at Entry Positive	
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 25-29, Female,	9,749
	Newly Identified Negative	
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 25-29, Female,	580
	Newly Identified Positive	
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 30-34, Female,	1,694
	Known at Entry Positive	
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 30-34, Female,	6,347
	Newly Identified Negative	
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 30-34, Female,	363
	Newly Identified Positive	
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 35-39, Female,	1,385
	Known at Entry Positive	
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 35-39, Female,	3,293
	Newly Identified Negative	
	PMTCT_STAT_N_DSD_Age_Sex_	400
	KnownNewResult 35-39, Female,	182
·		



	Newly Identified Positive	
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 40-49, Female,	637
	Known at Entry Positive	
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 40-49, Female,	1,300
	Newly Identified Negative	
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 40-49, Female,	12
	Newly Identified Positive	
	PMTCT_STAT_N_DSD_Age_Sex	44.700
	25-29, Female	11,732
	PMTCT_STAT_N_DSD_Age_Sex	9.405
	30-34, Female	8,405
	PMTCT_STAT_N_DSD_Age_Sex	4 074
	35-39, Female	4,874
	PMTCT_STAT_N_DSD_Age_Sex	1.050
	40-49, Female	1,952
	PMTCT_STAT_TA Number and	
	percentage of pregnant women	
	with known status (includes women	104 %
	who were tested for HIV and	
	received their results) (TA)	
	Number of pregnant women with	
	known HIV status (includes women	24,275
	who were tested for HIV and	_ :,_: 0
PMTCT_STAT_TA	received their results)	
	Number of new ANC and L&D	23,281
	clients	-,
	By Age (Denominator): 15-19	2,201
	By Age (Denominator): 20-24	6,977
	By known positives: 15-19	32
	By known positives: 20-24	137
	By new positives: 15-19	161



By new positives: 20-24	157
By new negatives: 15-19	1,828
By new negatives: 20-24	6,634
By Age (Numerator): : 15-19	2,020
By Age (Numerator): 20-24	6,383
PMTCT_STAT_D_TA_Age_Sex	·
25-29, Female	6,182
PMTCT_STAT_D_TA_Age_Sex	
30-34, Female	4,597
PMTCT_STAT_D_TA_Age_Sex	
35-39, Female	2,397
PMTCT_STAT_D_TA_Age_Sex	
40-49, Female	927
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 25-29, Female,	1,317
Known at Entry Positive	
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 25-29, Female,	5,364
Newly Identified Negative	
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 25-29, Female,	277
Newly Identified Positive	
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 30-34, Female,	486
Known at Entry Positive	
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 30-34, Female,	3,900
Newly Identified Negative	
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 30-34, Female,	193
Newly Identified Positive	
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 35-39, Female,	527
Known at Entry Positive	



	PMTCT_STAT_N_TA_Age_Sex_K	
	nownNewResult 35-39, Female,	1,777
	Newly Identified Negative	
	PMTCT_STAT_N_TA_Age_Sex_K	
	nownNewResult 35-39, Female,	149
	Newly Identified Positive	
	PMTCT_STAT_N_TA_Age_Sex_K	
	nownNewResult 40-49, Female,	264
	Known at Entry Positive	
	PMTCT_STAT_N_TA_Age_Sex_K	
	nownNewResult 40-49, Female,	726
	Newly Identified Negative	
	PMTCT_STAT_N_TA_Age_Sex_K	
	nownNewResult 40-49, Female,	3
	Newly Identified Positive	
	PMTCT_STAT_N_TA_Age_Sex	6,462
	25-29, Female	
	PMTCT_STAT_N_TA_Age_Sex	
	30-34, Female	4,184
	PMTCT_STAT_N_TA_Age_Sex	
	35-39, Female	2,196
	PMTCT_STAT_N_TA_Age_Sex	
	40-49, Female	871
	PMTCT_ART_DSD Percentage of	
	HIV-positive pregnant women who	
	received ART to reduce risk of	16 %
	mother-to-child-transmission	
	(MTCT) during pregnancy	
	Number of HIV-positive pregnant	
PMTCT_ART_DSD	women who received ART to	
	reduce risk of	7,333
	mother-to-child-transmission	
	(MTCT) during pregnancy	
	Number of pregnant women with	
	indifiber of pregnant women with	47,281



	who were tested for HIV and	
	received their results)	
	New on ART	1,790
	Already on ART at beginning of current pregnancy	5,543
	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	13 %
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,214
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	24,275
	New on ART	814
	Already on ART at beginning of current pregnancy	2,400
	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	54,306
VMMC_CIRC_DSD	By Age: 15-19	26,146
	By Age: 20-24	15,862
	By Age: 25-29	12,298
	By circumcision technique: Surgical VMMC	38,087
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure	n/a



	1	
	prophylaxis (PrEP) to prevent HIV	
	infection in the reporting period.	
	Number of individuals who have	
	been newly enrolled on oral	
	antiretroviral pre-exposure	4,759
	prophylaxis (PrEP) in the reporting	
	period to prevent HIV infection	
	Female 15-19	1,263
	Female 20-24	3,497
	FSW	240
	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	1,868
	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	157,953
PP_PREV_DSD	Age/sex: 10-14 Male	410
	Age/sex: 15-19 Male	13,064
	Age/sex: 20-24 Male	16,756
	Age/sex: 10-14 Female	6,204
	Age/sex: 15-19 Female	35,684
	Age/sex: 20-24 Female	39,578
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	11,262
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	5,427
	PP_PREV_N_DSD_Age_Sex_v2	6,755



	30-34, Female	
	PP_PREV_N_DSD_Age_Sex_v2	6.040
	30-34, Male	6,910
	PP_PREV_N_DSD_Age_Sex_v2	
	35-39, Female	6,828
	PP_PREV_N_DSD_Age_Sex_v2	
	35-39, Male	6,054
	PP_PREV_N_DSD_Age_Sex_v2	
	40-49, Female	5,416
	PP_PREV_N_DSD_Age_Sex_v2	2,336
	40-49, Male	
	KP_PREV_DSD Percentage of key	
	populations reached with individual	
	and/or small group level HIV	n/a
	preventive interventions that are	
	based on evidence and/or meet the	
	minimum standards required (DSD)	
	Number of key populations reached	
	with individual and/or small group	
	level HIV preventive interventions	14,946
	that are based on evidence and/or	14,940
	meet the minimum standards	
WD DDEV DOD	required	
KP_PREV_DSD	By key population type: Men who	
	have sex with men who are NOT	
	sex workers (Numerator: Number	
	of key populations reached with	0.045
	individual and/or small group level	3,915
	HIV preventive interventions that	
	are based on evidence and/or meet	
	the minimum standards required)	
	By key population type:	
	Transgender who are NOT sex	
	workers (Numerator: Number of	45
	key populations reached with	
	key populations readiled with	



Γ		
	individual and/or small group level	
	HIV preventive interventions that	
	are based on evidence and/or meet	
	the minimum standards required)	
	By key population type: Female	
	sex workers (FSW) (Numerator:	
	Number of key populations reached	
	with individual and/or small group	10,986
	level HIV preventive interventions	10,900
	that are based on evidence and/or	
	meet the minimum standards	
l	required)	
	Number of individuals who received	
	T&C services for HIV and received	E0 040
	their test results during the past 12	50,049
	months	
	Service Delivery Point (Facility)	70
	Inpatient: 10-14, Female, Negative	73
	Service Delivery Point (Facility)	
	Inpatient: 10-14, Female, Positive	6
	Service Delivery Point (Facility)	
	Inpatient: 10-14, Male, Negative	46
	Service Delivery Point (Facility)	
HTC_TST_TA	Inpatient: 10-14, Male, Positive	3
· · · · · · · · · · · · · · · · · · ·	Service Delivery Point (Facility)	
	Inpatient: 15-19, Female, Negative	274
	Service Delivery Point (Facility)	
	Inpatient: 15-19, Female, Positive	53
	Service Delivery Point (Facility)	
	Inpatient: 15-19, Male, Negative	307
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	26
	-	
	Service Delivery Point (Facility)	269
	Inpatient: 20-24, Female, Negative	
	Service Delivery Point (Facility)	45



Inpatient: 20-24, Female, Positive Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive Service Delivery Point (Facility) Inpatient: 50+, Female, Negative Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Positive Service Delivery Point (Facility) Inpatient: -1, Negative Service Delivery Point (Facility) Inpatient: -1-9, Negative Service Delivery Point (Facility) Inpatient: -1-9, Positive Service Delivery Point (Facility) Inpatient: -1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative		
Inpatient: 20-24, Male, Negative Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive Service Delivery Point (Facility) Inpatient: 50+, Female, Negative Service Delivery Point (Facility) Inpatient: 50+, Female, Negative Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Positive Service Delivery Point (Facility) Inpatient: -1, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 15-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	Inpatient: 20-24, Female, Positive	
Inpatient: 20-24, Male, Negative Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive Service Delivery Point (Facility) Inpatient: 50+, Female, Negative Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Positive Service Delivery Point (Facility) Inpatient: -1, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	Service Delivery Point (Facility)	440
Inpatient: 20-24, Male, Positive Service Delivery Point (Facility) Inpatient: 50+, Female, Negative Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Positive Service Delivery Point (Facility) Inpatient: <1, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	Inpatient: 20-24, Male, Negative	443
Inpatient: 20-24, Male, Positive Service Delivery Point (Facility) Inpatient: 50+, Female, Negative Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 41, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	Service Delivery Point (Facility)	38
Inpatient: 50+, Female, Negative Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Positive Service Delivery Point (Facility) Inpatient: -1, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Inpatient: 20-24, Male, Positive	
Inpatient: 50+, Female, Negative Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Positive Service Delivery Point (Facility) Inpatient: -1, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Service Delivery Point (Facility)	338
Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Positive Service Delivery Point (Facility) Inpatient: -1, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Inpatient: 50+, Female, Negative	330
Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Positive Service Delivery Point (Facility) Inpatient: <1, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Service Delivery Point (Facility)	30
Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Positive Service Delivery Point (Facility) Inpatient: <1, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Inpatient: 50+, Female, Positive	
Inpatient: 50+, Male, Negative Service Delivery Point (Facility) Inpatient: 50+, Male, Positive Service Delivery Point (Facility) Inpatient: <1, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, 218 Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, 732 Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Service Delivery Point (Facility)	334
Inpatient: 50+, Male, Positive Service Delivery Point (Facility) Inpatient: <1, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Inpatient: 50+, Male, Negative	334
Inpatient: 50+, Male, Positive Service Delivery Point (Facility) Inpatient: <1, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Service Delivery Point (Facility)	15
Inpatient: <1, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Inpatient: 50+, Male, Positive	15
Inpatient: <1, Negative Service Delivery Point (Facility) Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Service Delivery Point (Facility)	10
Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Inpatient: <1, Negative	19
Inpatient: 1-9, Negative Service Delivery Point (Facility) Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Service Delivery Point (Facility)	200
Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Inpatient: 1-9, Negative	200
Inpatient: 1-9, Positive Service Delivery Point (Facility) Other PITC: 10-14, Female, 218 Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, 732 Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Service Delivery Point (Facility)	4
Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Inpatient: 1-9, Positive	4
Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Service Delivery Point (Facility)	
Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Other PITC: 10-14, Female,	218
Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Negative	
Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Service Delivery Point (Facility)	1./1
Other PITC: 15-19, Female, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Other PITC: 10-14, Male, Negative	141
Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Service Delivery Point (Facility)	
Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Other PITC: 15-19, Female,	732
Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Negative	
Other PITC: 15-19, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Service Delivery Point (Facility)	1 087
Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Other PITC: 15-19, Male, Negative	1,007
Other PITC: 15-19, Male, Positive Service Delivery Point (Facility) Other PITC: 20-24, Female, 645	Service Delivery Point (Facility)	110
Other PITC: 20-24, Female, 645	Other PITC: 15-19, Male, Positive	113
	Service Delivery Point (Facility)	
Negative	Other PITC: 20-24, Female,	645
	Negative	



Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative Service Delivery Point (Facility)
Other PITC: 20-24, Male, Negative Service Delivery Point (Facility)
Service Delivery Point (Facility)
Other PITC: 20-24, Male, Positive
Service Delivery Point (Facility) Other PITC: 50+, Female, Negative
Service Delivery Point (Facility) Other PITC: 50+, Female, Positive
Service Delivery Point (Facility) Other PITC: 50+, Male, Negative
Service Delivery Point (Facility) Other PITC: 50+, Male, Positive
Service Delivery Point (Facility) Other PITC: <1, Negative
Service Delivery Point (Facility) Other PITC: 1-9, Negative
Service Delivery Point (Facility) Other PITC: 1-9, Positive
Service Delivery Point (Facility) TB: 10-14, Female, Negative
Service Delivery Point (Facility) TB: 10-14, Female, Positive
Service Delivery Point (Facility) TB: 17
Service Delivery Point (Facility) TB: 10-14, Male, Positive
Service Delivery Point (Facility) TB: 15-19, Female, Negative
10 10, 1 officio, 140gativo
Service Delivery Point (Facility) TB: 15-19, Female, Positive



15-19, Male, Negative Service Delivery Point (Facility) TB: 15-19, Male, Positive Service Delivery Point (Facility) TB: 20-24, Female, Negative Service Delivery Point (Facility) TB: 20-24, Female, Positive Service Delivery Point (Facility) TB: 20-24, Female, Positive Service Delivery Point (Facility) TB: 20-24, Male, Negative Service Delivery Point (Facility) TB: 20-24, Male, Positive Service Delivery Point (Facility) TB: 50+, Female, Negative Service Delivery Point (Facility) TB: 50+, Female, Positive Service Delivery Point (Facility) TB: 50+, Male, Negative Service Delivery Point (Facility) TB: 50+, Male, Negative Service Delivery Point (Facility) TB: 41, Negative Service Delivery Point (Facility) TB: 42, Negative Service Delivery Point (Facility) TB: 43, Negative Service Delivery Point (Facility) TB: 44 Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) Index: 15-19, Female, Negative Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative			
15-19, Male, Positive Service Delivery Point (Facility) TB: 20-24, Female, Negative Service Delivery Point (Facility) TB: 20-24, Female, Positive Service Delivery Point (Facility) TB: 20-24, Female, Negative Service Delivery Point (Facility) TB: 20-24, Male, Negative Service Delivery Point (Facility) TB: 20-24, Male, Positive Service Delivery Point (Facility) TB: 50+, Female, Negative Service Delivery Point (Facility) TB: 50+, Female, Positive Service Delivery Point (Facility) TB: 50+, Male, Negative Service Delivery Point (Facility) TB: 50+, Male, Positive Service Delivery Point (Facility) TB: 50+, Male, Positive Service Delivery Point (Facility) TB: <1, Negative Service Delivery Point (Facility) TB: <1, Positive Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) Index: 15-19, Female, Negative Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) Index: 15-19, Male, Negative	15-19,	Male, Negative	
20-24, Female, Negative Service Delivery Point (Facility) TB: 20-24, Female, Positive Service Delivery Point (Facility) TB: 20-24, Male, Negative Service Delivery Point (Facility) TB: 20-24, Male, Positive Service Delivery Point (Facility) TB: 50+, Female, Negative Service Delivery Point (Facility) TB: 50+, Female, Positive Service Delivery Point (Facility) TB: 50+, Male, Positive Service Delivery Point (Facility) TB: 50+, Male, Negative Service Delivery Point (Facility) TB: 50+, Male, Positive Service Delivery Point (Facility) TB: 41, Negative Service Delivery Point (Facility) TB: 41, Positive Service Delivery Point (Facility) TB: 42, Positive Service Delivery Point (Facility) TB: 43, Positive Service Delivery Point (Facility) TB: 44 Service Delivery Point (Facility) Index: 15-19, Female, Negative Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility)			4
20-24, Female, Positive Service Delivery Point (Facility) TB: 20-24, Male, Negative Service Delivery Point (Facility) TB: 20-24, Male, Positive Service Delivery Point (Facility) TB: 50+, Female, Negative Service Delivery Point (Facility) TB: 50+, Female, Positive Service Delivery Point (Facility) TB: 50+, Male, Negative Service Delivery Point (Facility) TB: 50+, Male, Negative Service Delivery Point (Facility) TB: 20-24, Male, Positive Service Delivery Point (Facility) TB: 20-25, Male, Positive Service Delivery Point (Facility) TB: 21-1, Negative Service Delivery Point (Facility) TB: 22-27 Service Delivery Point (Facility) TB: 23-38 24-38 25-38 26-38 26-38 26-38 27 27 27 28 29 20 20 21 22 23 24 25 26 26 27 27 28 29 20 20 20 20 20 20 20 20 20		` ` ',	90
20-24, Male, Negative Service Delivery Point (Facility) TB: 20-24, Male, Positive Service Delivery Point (Facility) TB: 50+, Female, Negative Service Delivery Point (Facility) TB: 50+, Female, Positive Service Delivery Point (Facility) TB: 50+, Male, Negative Service Delivery Point (Facility) TB: 50+, Male, Negative Service Delivery Point (Facility) TB: 50+, Male, Positive Service Delivery Point (Facility) TB: <1, Negative Service Delivery Point (Facility) TB: <1, Positive Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) Index: 15-19, Female, Negative Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility)		, , , , , , , , , , , , , , , , , , , ,	3
20-24, Male, Positive Service Delivery Point (Facility) TB: 50+, Female, Negative Service Delivery Point (Facility) TB: 50+, Female, Positive Service Delivery Point (Facility) TB: 50+, Male, Negative Service Delivery Point (Facility) TB: 50+, Male, Positive Service Delivery Point (Facility) TB: 50+, Male, Positive Service Delivery Point (Facility) TB: <1, Negative Service Delivery Point (Facility) TB: <1, Positive Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) Index: 15-19, Female, Negative Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility)		, , , , , , , , , , , , , , , , , , , ,	63
Service Delivery Point (Facility) TB: 50+, Female, Positive Service Delivery Point (Facility) TB: 50+, Male, Negative Service Delivery Point (Facility) TB: 50+, Male, Negative Service Delivery Point (Facility) TB: 50+, Male, Positive Service Delivery Point (Facility) TB: <1, Negative Service Delivery Point (Facility) TB: <1, Positive Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) Index: 15-19, Female, Negative Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility)		, , , , , , , , , , , , , , , , , , , ,	3
Service Delivery Point (Facility) TB: 50+, Male, Negative Service Delivery Point (Facility) TB: 50+, Male, Negative Service Delivery Point (Facility) TB: 50+, Male, Positive Service Delivery Point (Facility) TB: <1, Negative Service Delivery Point (Facility) TB: <1, Positive Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) Index: 15-19, Female, Negative Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative		` ` ,	36
50+, Male, Negative Service Delivery Point (Facility) TB: 50+, Male, Positive Service Delivery Point (Facility) TB: <1, Negative Service Delivery Point (Facility) TB: <1, Positive Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) Index: 15-19, Female, Negative Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility)		, , , , , , , , , , , , , , , , , , , ,	2
Service Delivery Point (Facility) TB: <1, Negative Service Delivery Point (Facility) TB: <1, Positive Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) Index: 15-19, Female, Negative Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative		, , , , , , , , , , , , , , , , , , , ,	64
<1, Negative Service Delivery Point (Facility) TB: <1, Positive Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) Index: 15-19, Female, Negative Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) 97		, , , , , , , , , , , , , , , , , , , ,	2
<1, Positive Service Delivery Point (Facility) TB: 1-9, Negative Service Delivery Point (Facility) Index: 15-19, Female, Negative Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) 97			27
1-9, Negative Service Delivery Point (Facility) Index: 15-19, Female, Negative Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) 97		, , , , , , , , , , , , , , , , , , , ,	2
Index: 15-19, Female, Negative Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) 97		` ` ',	44
Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) 97		` ` ',	358
Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) 97		, , , , ,	79
97	Service	e Delivery Point (Facility)	496
		` ` ',	97
Service Delivery Point (Facility) 293	Service	e Delivery Point (Facility)	293



Index: 20-24, Female, Negative	
Service Delivery Point (Facility)	77
Index: 20-24, Female, Positive	77
Service Delivery Point (Facility)	700
Index: 20-24, Male, Negative	722
Service Delivery Point (Facility)	50
Index: 20-24, Male, Positive	58
Service Delivery Point (Facility)	650
Index: 50+, Female, Negative	650
Service Delivery Point (Facility)	76
Index: 50+, Female, Positive	76
Service Delivery Point (Facility)	578
Index: 50+, Male, Negative	576
Service Delivery Point (Facility)	27
Index: 50+, Male, Positive	21
Service Delivery Point (Facility)	1 457
ANC: 15-19, Negative	1,457
Service Delivery Point (Facility)	71
ANC: 15-19, Positive	71
Service Delivery Point (Facility)	3,258
ANC: 20-24, Negative	3,236
Service Delivery Point (Facility)	188
ANC: 20-24, Positive	100
Service Delivery Point (Facility)	238
VCT: 10-14, Female, Negative	230
Service Delivery Point (Facility)	3
VCT: 10-14, Female, Positive	3
Service Delivery Point (Facility)	128
VCT: 10-14, Male, Negative	120
Service Delivery Point (Facility)	647
VCT: 15-19, Female, Negative	047
Service Delivery Point (Facility)	20
VCT: 15-19, Female, Positive	20
Service Delivery Point (Facility)	757



VCT: 15-19, Male, Negative	
Service Delivery Point (Facility) VCT: 15-19, Male, Positive	60
Service Delivery Point (Facility)	050
VCT: 20-24, Female, Negative	658
Service Delivery Point (Facility) VCT: 20-24, Female, Positive	45
Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,058
Service Delivery Point (Facility) VCT: 20-24, Male, Positive	42
Service Delivery Point (Facility) VCT: 50+, Female, Negative	809
Service Delivery Point (Facility) VCT: 50+, Female, Positive	39
Service Delivery Point (Facility) VCT: 50+, Male, Negative	813
Service Delivery Point (Facility) VCT: 50+, Male, Positive	13
Service Delivery Point (Facility) VCT: <1, Negative	36
Service Delivery Point (Facility) VCT: 1-9, Negative	325
Service Delivery Point (Facility) VCT: 1-9, Positive	17
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Female, Negative	4
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Female, Positive	85
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Male, Negative	219
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Male, Positive	105
HTS_TST_N_TA_Index_Age_Sex_	580



Result 30-34, Female, Negative	
HTS_TST_N_TA_Index_Age_Sex_	450
Result 30-34, Female, Positive	156
HTS_TST_N_TA_Index_Age_Sex_	4.000
Result 30-34, Male, Negative	1,229
HTS_TST_N_TA_Index_Age_Sex_	20
Result 30-34, Male, Positive	36
HTS_TST_N_TA_Index_Age_Sex_	500
Result 35-39, Female, Negative	580
HTS_TST_N_TA_Index_Age_Sex_	0.7
Result 35-39, Female, Positive	87
HTS_TST_N_TA_Index_Age_Sex_	222
Result 35-39, Male, Negative	223
HTS_TST_N_TA_Index_Age_Sex_	10
Result 35-39, Male, Positive	19
HTS_TST_N_TA_Index_Age_Sex_	4.005
Result 40-49, Female, Negative	1,005
HTS_TST_N_TA_Index_Age_Sex_	59
Result 40-49, Female, Positive	5 9
HTS_TST_N_TA_Index_Age_Sex_	295
Result 40-49, Male, Negative	293
HTS_TST_N_TA_Inpat_Age_Sex_	86
Result 25-29, Female, Negative	00
HTS_TST_N_TA_Inpat_Age_Sex_	58
Result 25-29, Female, Positive	30
HTS_TST_N_TA_Inpat_Age_Sex_	111
Result 25-29, Male, Negative	111
HTS_TST_N_TA_Inpat_Age_Sex_	77
Result 25-29, Male, Positive	7.7
HTS_TST_N_TA_Inpat_Age_Sex_	420
Result 30-34, Female, Negative	720
HTS_TST_N_TA_Inpat_Age_Sex_	109
Result 30-34, Female, Positive	109
HTS_TST_N_TA_Inpat_Age_Sex_	786



Result 30-34, Male, Negative	
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Male, Positive	28
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Female, Negative	333
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Female, Positive	65
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Male, Negative	153
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Male, Positive	16
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Female, Negative	514
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Female, Positive	39
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Male, Negative	181
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Male, Positive	11
HTS_TST_N_TA_OtPITC_Age_Se x_Result 25-29, Female, Negative	23
HTS_TST_N_TA_OtPITC_Age_Se x_Result 25-29, Female, Positive	77
HTS_TST_N_TA_OtPITC_Age_Se x_Result 25-29, Male, Negative	471
HTS_TST_N_TA_OtPITC_Age_Se x_Result 25-29, Male, Positive	121
HTS_TST_N_TA_OtPITC_Age_Se x_Result 30-34, Female, Negative	1,177
HTS_TST_N_TA_OtPITC_Age_Se x_Result 30-34, Female, Positive	214
HTS_TST_N_TA_OtPITC_Age_Se x_Result 30-34, Male, Negative	2,548
HTS_TST_N_TA_OtPITC_Age_Se	34



x_Re	esult 30-34, Male, Positive	
HTS.	_TST_N_TA_OtPITC_Age_Se	1 227
x_Re	esult 35-39, Female, Negative	1,237
нтs.	_TST_N_TA_OtPITC_Age_Se	90
x_Re	esult 35-39, Female, Positive	89
нтѕ	_TST_N_TA_OtPITC_Age_Se	400
x_Re	esult 35-39, Male, Negative	490
нтs.	_TST_N_TA_OtPITC_Age_Se	2
x_Re	esult 35-39, Male, Positive	2
нтѕ	_TST_N_TA_OtPITC_Age_Se	2.000
x_Re	esult 40-49, Female, Negative	2,090
HTS.	_TST_N_TA_OtPITC_Age_Se	57
x_Re	esult 40-49, Female, Positive	57
HTS.	_TST_N_TA_OtPITC_Age_Se	652
x_Re	esult 40-49, Male, Negative	052
HTS.	_TST_N_TA_OtPITC_Age_Se	0
x_Re	esult 40-49, Male, Positive	U
HTS.	_TST_N_TA_PMTCT_Age_Se	2,879
x_Re	esult 25-29, Female, Negative	2,079
HTS.	_TST_N_TA_PMTCT_Age_Se	188
x_Re	esult 25-29, Female, Positive	100
HTS.	_TST_N_TA_PMTCT_Age_Se	2,051
x_Re	esult 30-34, Female, Negative	2,001
HTS.	_TST_N_TA_PMTCT_Age_Se	158
x_Re	esult 30-34, Female, Positive	100
HTS.	_TST_N_TA_PMTCT_Age_Se	955
x_Re	esult 35-39, Female, Negative	300
HTS.	_TST_N_TA_PMTCT_Age_Se	81
x_Re	esult 35-39, Female, Positive	
HTS.	_TST_N_TA_PMTCT_Age_Se	369
x_Re	esult 40-49, Female, Negative	
HTS.	_TST_N_TA_PMTCT_Age_Se	41
x_Re	esult 40-49, Female, Positive	71
HTS.	_TST_N_TA_TBC_Age_Sex_	73



Result 25-29, Female, Negative	
HTS_TST_N_TA_TBC_Age_Sex_	4
Result 25-29, Female, Positive	4
HTS_TST_N_TA_TBC_Age_Sex_	04
Result 25-29, Male, Negative	81
HTS_TST_N_TA_TBC_Age_Sex_	4
Result 25-29, Male, Positive	4
HTS_TST_N_TA_TBC_Age_Sex_	04
Result 30-34, Female, Negative	81
HTS_TST_N_TA_TBC_Age_Sex_	0
Result 30-34, Female, Positive	3
HTS_TST_N_TA_TBC_Age_Sex_	0.4
Result 30-34, Male, Negative	64
HTS_TST_N_TA_TBC_Age_Sex_	4
Result 30-34, Male, Positive	4
HTS_TST_N_TA_TBC_Age_Sex_	04
Result 35-39, Female, Negative	81
HTS_TST_N_TA_TBC_Age_Sex_	4
Result 35-39, Female, Positive	4
HTS_TST_N_TA_TBC_Age_Sex_	00
Result 35-39, Male, Negative	90
HTS_TST_N_TA_TBC_Age_Sex_	1
Result 35-39, Male, Positive	1
HTS_TST_N_TA_TBC_Age_Sex_	17
Result 40-49, Female, Negative	17
HTS_TST_N_TA_TBC_Age_Sex_	1
Result 40-49, Female, Positive	1
HTS_TST_N_TA_TBC_Age_Sex_	17
Result 40-49, Male, Negative	17
HTS_TST_N_TA_TBC_Age_Sex_	2
Result 40-49, Male, Positive	2
HTS_TST_N_TA_VCT_Age_Sex_	198
Result 25-29, Female, Negative	130
HTS_TST_N_TA_VCT_Age_Sex_	60



	·	
	Result 25-29, Female, Positive	
	HTS_TST_N_TA_VCT_Age_Sex_	204
	Result 25-29, Male, Negative	281
	HTS_TST_N_TA_VCT_Age_Sex_	90
	Result 25-29, Male, Positive	80
	HTS_TST_N_TA_VCT_Age_Sex_	004
	Result 30-34, Female, Negative	984
	HTS_TST_N_TA_VCT_Age_Sex_	00
	Result 30-34, Female, Positive	93
	HTS_TST_N_TA_VCT_Age_Sex_	4.007
	Result 30-34, Male, Negative	1,907
	HTS_TST_N_TA_VCT_Age_Sex_	20
	Result 30-34, Male, Positive	33
	HTS_TST_N_TA_VCT_Age_Sex_	700
	Result 35-39, Female, Negative	799
	HTS_TST_N_TA_VCT_Age_Sex_	60
	Result 35-39, Female, Positive	68
	HTS_TST_N_TA_VCT_Age_Sex_	270
	Result 35-39, Male, Negative	372
	HTS_TST_N_TA_VCT_Age_Sex_	0.5
	Result 35-39, Male, Positive	25
	HTS_TST_N_TA_VCT_Age_Sex_	4 222
	Result 40-49, Female, Negative	1,232
	HTS_TST_N_TA_VCT_Age_Sex_	20
	Result 40-49, Female, Positive	36
	HTS_TST_N_TA_VCT_Age_Sex_	405
	Result 40-49, Male, Negative	465
	HTS_TST_N_TA_VCT_Age_Sex_	47
	Result 40-49, Male, Positive	17
	TB_STAT_DSD Percentage of	
	registered new and relapsed TB	
TB_STAT_DSD	cases with documented HIV status.	95 %



T.	
Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,557
Total number of registered new and relapsed TB cases, during the reporting period.	5,849
Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	267
Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,903
Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	229
Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,158
Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	298
Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,049



	1	1
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	265
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,238
	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	95 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,985
	Total number of registered new and relapsed TB cases, during the reporting period.	2,090
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	203
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	278
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	691
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB	918



	cases, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	224
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	901
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	183
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	677
	HTS_SELF_N_DSD	15,646
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	2,616
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Unassisted	2,400
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Unassisted	4,251
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	4,800
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	2,400



	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	6,769
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female,	4,800
	Unassisted HTS_SELF_N_DSD_Age_Sex_HI	
	VSelfTest 30-34, Male, Unassisted	3,488
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Unassisted	3,000
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Unassisted	6,000
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Unassisted	9,600
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	2,093
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Unassisted	2,400
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Unassisted	5,400
	HTS_SELF_N_DSD_HIVSelfTest Unassisted	15,646
	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	345,827
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	317
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	25
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	211
	Service Delivery Point (Facility)	12



Inpatient: 10-14, Male, Positive		
Service Delivery Point (Facility)	000	
Inpatient: 15-19, Female, Negative	888	
Service Delivery Point (Facility)		
Inpatient: 15-19, Female, Positive	173	
Service Delivery Point (Facility)		
Inpatient: 15-19, Male, Negative	1,095	
Service Delivery Point (Facility)		
Inpatient: 15-19, Male, Positive	107	
Service Delivery Point (Facility)		
Inpatient: 20-24, Female, Negative	996	
Service Delivery Point (Facility)		
Inpatient: 20-24, Female, Positive	208	
Service Delivery Point (Facility)		
Inpatient: 20-24, Male, Negative	1,867	
Service Delivery Point (Facility)		
Inpatient: 20-24, Male, Positive	148	
Service Delivery Point (Facility)		
Inpatient: 50+, Female, Negative	1,394	
Service Delivery Point (Facility)		
Inpatient: 50+, Female, Positive	158	
Service Delivery Point (Facility)		
Inpatient: 50+, Male, Negative	1,460	
Service Delivery Point (Facility)		
Inpatient: 50+, Male, Positive	76	
Service Delivery Point (Facility)		
Inpatient: <1, Negative	90	
Service Delivery Point (Facility)	2.42	
Inpatient: 1-9, Negative	942	
Service Delivery Point (Facility)		
Inpatient: 1-9, Positive	22	
Service Delivery Point (Community)		
Mobile Testing: 15-19, Female,	1,834	
Negative		



Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	79
Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	1,222
Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	17
Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	2,445
Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	42
Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,834
Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	62
Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	609
Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	15
Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	406
Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	9
Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,036



Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	611
Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	3,720
Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	26
Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	4,884
Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	422
Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	4,205
Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	370
Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	7,803
Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	250
Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	5,784
Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	296
Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	5,362
Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	134
Service Delivery Point (Facility)Other PITC: <1, Negative	358
Service Delivery Point (Facility) Other PITC: 1-9, Negative	4,045



Service Delivery Point (Facility) Other PITC: 1-9, Positive	146
Service Delivery Point (Community)	1,728
Other: 15-19, Female, Negative	.,. 20
Service Delivery Point (Community)	2
Other: 15-19, Female, Positive	
Service Delivery Point (Community) Other: 15-19, Male, Negative	2,390
Service Delivery Point (Community)	295
Other: 15-19, Male, Positive	
Service Delivery Point (Community) Other: 20-24, Female, Negative	1,405
Service Delivery Point (Community) Other: 20-24, Female, Positive	184
Service Delivery Point (Community) Other: 20-24, Male, Negative	3,407
Service Delivery Point (Community) Other: 20-24, Male, Positive	135
Service Delivery Point (Community) Other: 50+, Female, Negative	3,097
Service Delivery Point (Community) Other: 50+, Female, Positive	182
Service Delivery Point (Community) Other: 50+, Male, Negative	2,757
Service Delivery Point (Community) Other: 50+, Male, Positive	68
Service Delivery Point (Facility) TB: 10-14, Female, Negative	35
Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
Service Delivery Point (Facility) TB: 10-14, Male, Negative	65
Service Delivery Point (Facility) TB: 10-14, Male, Positive	4



Service Delivery Point (Facility) TB: 15-19, Female, Negative Service Delivery Point (Facility) TB:	
15-19, Female, Positive	
Service Delivery Point (Facility) TB: 15-19, Male, Negative 65	
Service Delivery Point (Facility) TB: 13	
Service Delivery Point (Facility) TB: 20-24, Female, Negative	
Service Delivery Point (Facility) TB: 20-24, Female, Positive	
Service Delivery Point (Facility) TB: 20-24, Male, Negative	
Service Delivery Point (Facility) TB: 20-24, Male, Positive	
Service Delivery Point (Facility) TB: 128	
Service Delivery Point (Facility) TB: 50+, Female, Positive	
Service Delivery Point (Facility) TB: 50+, Male, Negative	
Service Delivery Point (Facility) TB: 50+, Male, Positive	
Service Delivery Point (Facility) TB: 98	
Service Delivery Point (Facility) TB: <a><<a><<a><<a><<a> <	
Service Delivery Point (Facility) TB: 1-9, Negative	
Service Delivery Point (Facility) VMMC: 15-19, Negative 6,755	
Service Delivery Point (Facility) VMMC: 20-24, Negative	



Service Delivery Point (Facility)	957
Service Delivery Point (Facility)	203
Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,289
Service Delivery Point (Facility) Index: 15-19, Male, Positive	234
Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,000
Service Delivery Point (Facility) Index: 20-24, Female, Positive	226
Service Delivery Point (Facility) Index: 20-24, Male, Negative	2,059
Service Delivery Point (Facility) Index: 20-24, Male, Positive	161
Service Delivery Point (Facility) Index: 50+, Female, Negative	1,698
Service Delivery Point (Facility) Index: 50+, Female, Positive	190
Service Delivery Point (Facility) Index: 50+, Male, Negative	1,517
Service Delivery Point (Facility) Index: 50+, Male, Positive	79
By Key Population: FSW, Negative	659
By Key Population: FSW, Positive	64
By Key Population: MSM, Negative	861
By Key Population: MSM, Positive	48
By Key Population: People in prisons and other enclosed settings, Negative	54
By Key Population: People in prisons and other enclosed settings, Positive	7
	Index: 15-19, Female, Negative Service Delivery Point (Facility) Index: 15-19, Female, Positive Service Delivery Point (Facility) Index: 15-19, Male, Negative Service Delivery Point (Facility) Index: 15-19, Male, Positive Service Delivery Point (Facility) Index: 20-24, Female, Negative Service Delivery Point (Facility) Index: 20-24, Female, Positive Service Delivery Point (Facility) Index: 20-24, Male, Negative Service Delivery Point (Facility) Index: 20-24, Male, Positive Service Delivery Point (Facility) Index: 50+, Female, Negative Service Delivery Point (Facility) Index: 50+, Female, Positive Service Delivery Point (Facility) Index: 50+, Female, Positive Service Delivery Point (Facility) Index: 50+, Male, Negative Service Delivery Point (Facility) Index: 50+, Male, Positive By Key Population: FSW, Negative By Key Population: FSW, Positive By Key Population: MSM, Positive By Key Population: MSM, Positive By Key Population: People in prisons and other enclosed settings, Negative By Key Population: People in prisons and other enclosed



By Key F	Population: TG, Negative	6
By Key F	Population: TG, Positive	1
	Delivery Point (Community) od: 15-19, Female,	2,710
	Delivery Point (Community) od: 15-19, Female, Positive	252
	Delivery Point (Community) od: 15-19, Male, Negative	2,227
	Delivery Point (Community) od: 15-19, Male, Positive	176
	Delivery Point (Community) od: 20-24, Female,	3,526
	Delivery Point (Community) od: 20-24, Female, Positive	342
	Delivery Point (Community) od: 20-24, Male, Negative	2,790
	Delivery Point (Community) od: 20-24, Male, Positive	397
	Delivery Point (Community) od: 50+, Female, Negative	2,009
	Delivery Point (Community) od: 50+, Female, Positive	171
	Delivery Point (Community) od: 50+, Male, Negative	1,448
	Delivery Point (Community) od: 50+, Male, Positive	361
	Delivery Point (Facility) -19, Negative	7,646
	Delivery Point (Facility) -19, Positive	325
	Delivery Point (Facility) -24, Negative	13,831



	Service Delivery Point (Facility) ANC: 20-24, Positive	541
S	Service Delivery Point (Facility) /CT: 10-14, Female, Negative	613
S	Service Delivery Point (Facility) /CT: 10-14, Female, Positive	1
	Service Delivery Point (Facility) /CT: 10-14, Male, Negative	429
	Service Delivery Point (Facility) /CT: 15-19, Female, Negative	2,287
	Service Delivery Point (Facility) /CT: 15-19, Female, Positive	12
	Service Delivery Point (Facility) /CT: 15-19, Male, Negative	2,945
	Service Delivery Point (Facility) /CT: 15-19, Male, Positive	250
	Service Delivery Point (Facility) /CT: 20-24, Female, Negative	2,446
	Service Delivery Point (Facility) /CT: 20-24, Female, Positive	179
	Service Delivery Point (Facility) /CT: 20-24, Male, Negative	4,577
	Service Delivery Point (Facility) /CT: 20-24, Male, Positive	131
	Service Delivery Point (Facility) /CT: 50+, Female, Negative	3,681
	Service Delivery Point (Facility) /CT: 50+, Female, Positive	156
	Service Delivery Point (Facility) /CT: 50+, Male, Negative	3,686
	Service Delivery Point (Facility) /CT: 50+, Male, Positive	59
	Service Delivery Point (Facility) /CT: <1, Negative	152



ervice Delivery Point (Facility) CT: 1-9, Negative	1,707
ervice Delivery Point (Facility) CT: 1-9, Positive	60
TS_TST_N_DSD_Index_Age_Se _Result 25-29, Female, Negative	76
TS_TST_N_DSD_Index_Age_Se _Result 25-29, Female, Positive	244
TS_TST_N_DSD_Index_Age_Se _Result 25-29, Male, Negative	693
TS_TST_N_DSD_Index_Age_Se _Result 25-29, Male, Positive	290
TS_TST_N_DSD_Index_Age_Se _Result 30-34, Female, Negative	1,571
TS_TST_N_DSD_Index_Age_Se _Result 30-34, Female, Positive	384
TS_TST_N_DSD_Index_Age_Se _Result 30-34, Male, Negative	3,585
TS_TST_N_DSD_Index_Age_Se _Result 30-34, Male, Positive	108
TS_TST_N_DSD_Index_Age_Se _Result 35-39, Female, Negative	1,647
TS_TST_N_DSD_Index_Age_Se _Result 35-39, Female, Positive	236
TS_TST_N_DSD_Index_Age_Se _Result 35-39, Male, Negative	769
TS_TST_N_DSD_Index_Age_Se _Result 35-39, Male, Positive	63
TS_TST_N_DSD_Index_Age_Se _Result 40-49, Female, Negative	2,734
TS_TST_N_DSD_Index_Age_Se _Result 40-49, Female, Positive	156
TS_TST_N_DSD_Index_Age_Se _Result 40-49, Male, Negative	1,002



HTS_TST_N_DSD_Index_Age_Se x_Result 40-49, Male, Positive	7
HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Female, Negative	210
HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Female, Positive	213
HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Male, Negative	608
HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Male, Positive	309
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Female, Negative	1,308
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Female, Positive	469
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Negative	3,161
HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Positive	100
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Negative	1,721
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Positive	228
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Negative	864
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Positive	29
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Negative	2,279
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	155
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	966
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	20



ı	T	1
Sex_	S_TST_N_DSD_MbMod_Age_ c_Result 25-29, Female, gative	1,427
	S_TST_N_DSD_MbMod_Age_ c_Result 25-29, Female, sitive	104
	S_TST_N_DSD_MbMod_Age_ c_Result 25-29, Male, Negative	203
	S_TST_N_DSD_MbMod_Age_ c_Result 25-29, Male, Positive	95
Sex_	S_TST_N_DSD_MbMod_Age_ c_Result 30-34, Female, gative	2,650
	S_TST_N_DSD_MbMod_Age_ c_Result 30-34, Female, sitive	16
	S_TST_N_DSD_MbMod_Age_ c_Result 30-34, Male, Negative	3,869
	S_TST_N_DSD_MbMod_Age_ c_Result 30-34, Male, Positive	87
Sex_	S_TST_N_DSD_MbMod_Age_ c_Result 35-39, Female, gative	1,019
	S_TST_N_DSD_MbMod_Age_ c_Result 35-39, Female, sitive	128
	S_TST_N_DSD_MbMod_Age_ c_Result 35-39, Male, Negative	815
	S_TST_N_DSD_MbMod_Age_ c_Result 35-39, Male, Positive	95
Sex_	S_TST_N_DSD_MbMod_Age_ c_Result 40-49, Female, gative	1,221
	S_TST_N_DSD_MbMod_Age_ c_Result 40-49, Female,	50



Positive	
HTS_TST_N_DSD_MbMod_Age_	2.1-
Sex_Result 40-49, Male, Negative	815
HTS_TST_N_DSD_MbMod_Age_	24
Sex_Result 40-49, Male, Positive	61
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 25-29, Female,	1,303
Negative	
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 25-29, Female,	344
Positive	
HTS_TST_N_DSD_NdxMod_Age_	2,424
Sex_Result 25-29, Male, Negative	2,424
HTS_TST_N_DSD_NdxMod_Age_	EE0
Sex_Result 25-29, Male, Positive	558
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 30-34, Female,	3,252
Negative	
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 30-34, Female,	331
Positive	
HTS_TST_N_DSD_NdxMod_Age_	4,128
Sex_Result 30-34, Male, Negative	7,120
HTS_TST_N_DSD_NdxMod_Age_	353
Sex_Result 30-34, Male, Positive	000
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 35-39, Female,	1,526
Negative	
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 35-39, Female,	374
Positive	
HTS_TST_N_DSD_NdxMod_Age_	1,907
Sex_Result 35-39, Male, Negative	.,
HTS_TST_N_DSD_NdxMod_Age_	507



Tr Tr	ı
Sex_Result 35-39, Male, Positive	
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 40-49, Female,	1,538
Negative	
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 40-49, Female,	683
Positive	
HTS_TST_N_DSD_NdxMod_Age_	0.004
Sex_Result 40-49, Male, Negative	2,934
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 40-49, Male, Positive	196
HTS_TST_N_DSD_OtPITC_Age_	
Sex_Result 25-29, Female,	853
Negative	
HTS_TST_N_DSD_OtPITC_Age_	
Sex_Result 25-29, Female,	375
Positive	
HTS_TST_N_DSD_OtPITC_Age_	
Sex_Result 25-29, Male, Negative	3,007
HTS_TST_N_DSD_OtPITC_Age_	
Sex_Result 25-29, Male, Positive	522
HTS_TST_N_DSD_OtPITC_Age_	
Sex_Result 30-34, Female,	5,705
Negative	
HTS_TST_N_DSD_OtPITC_Age_	
Sex_Result 30-34, Female,	821
Positive	
HTS_TST_N_DSD_OtPITC_Age_	
Sex_Result 30-34, Male, Negative	12,954
HTS_TST_N_DSD_OtPITC_Age_	
Sex_Result 30-34, Male, Positive	200
HTS_TST_N_DSD_OtPITC_Age_	
Sex_Result 35-39, Female,	6,949
Negative	-,
U '' -	



HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Positive	403
HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative	3,289
HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive	65
HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Negative	9,828
HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Positive	243
HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Male, Negative	3,840
HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Male, Positive	37
HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Female, Negative	45
HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Female, Positive	182
HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Male, Negative	1,027
HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Male, Positive	296
HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 30-34, Female, Negative	2,689
HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 30-34, Female, Positive	516
HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 30-34, Male, Negative	6,525



HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive		
Sex_Result 35-39, Female, Negative HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 35-39, Female, Positive HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 35-39, Male, Negative HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 35-39, Male, Positive HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Female, Negative HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Female, Negative HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Remale, Positive HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Male, Negative HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Male, Negative HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Male, Positive HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female, Negative HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female, Positive HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female, Negative HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female, Positive	_	69
Sex_Result 35-39, Female,	Sex_Result 35-39, Female,	2,883
Sex_Result 35-39, Male, Negative	Sex_Result 35-39, Female,	203
Sex_Result 35-39, Male, Positive	_	1,216
Sex_Result 40-49, Female, Negative HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Female, Positive HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Male, Negative HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Male, Positive HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female, HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female, HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female, HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female, Negative	_	2
Sex_Result 40-49, Female, Positive HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Male, Negative HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Male, Positive HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female, HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female, 472 Positive HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female, HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female, Sex_Resu	Sex_Result 40-49, Female,	4,786
Sex_Result 40-49, Male, Negative HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Male, Positive HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female, HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female, HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female, 472 Positive HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female, HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female, HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female, Sex_Re	Sex_Result 40-49, Female,	136
Sex_Result 40-49, Male, Positive HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female, HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female, HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female, HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female, Negative HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female,	_	1,511
Sex_Result 25-29, Female, Negative HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female, Positive HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female, Negative HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female, Sex_Result 30-34	_	2
Sex_Result 25-29, Female, 472 Positive HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female, 8,334 Negative HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female, 363 Positive	Sex_Result 25-29, Female,	11,603
Sex_Result 30-34, Female, 8,334 Negative HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 30-34, Female, 363 Positive	Sex_Result 25-29, Female,	472
Sex_Result 30-34, Female, 363 Positive	Sex_Result 30-34, Female,	8,334
HTS_TST_N_DSD_PMTCT_Age_ 4,193	Sex_Result 30-34, Female,	363
	HTS_TST_N_DSD_PMTCT_Age_	4,193



Sex_Result 35-39, Female,	
Negative	
HTS_TST_N_DSD_PMTCT_Age_	
Sex_Result 35-39, Female,	209
Positive	
HTS_TST_N_DSD_PMTCT_Age_	
Sex_Result 40-49, Female,	1,771
Negative	
HTS_TST_N_DSD_PMTCT_Age_	
Sex_Result 40-49, Female,	93
Positive	
HTS_TST_N_DSD_TBC_Age_Sex	255
_Result 25-29, Female, Negative	255
HTS_TST_N_DSD_TBC_Age_Sex	11
_Result 25-29, Female, Positive	11
HTS_TST_N_DSD_TBC_Age_Sex	290
_Result 25-29, Male, Negative	290
HTS_TST_N_DSD_TBC_Age_Sex	11
_Result 25-29, Male, Positive	11
HTS_TST_N_DSD_TBC_Age_Sex	289
_Result 30-34, Female, Negative	209
HTS_TST_N_DSD_TBC_Age_Sex	11
_Result 30-34, Female, Positive	11
HTS_TST_N_DSD_TBC_Age_Sex	222
_Result 30-34, Male, Negative	222
HTS_TST_N_DSD_TBC_Age_Sex	11
_Result 30-34, Male, Positive	11
HTS_TST_N_DSD_TBC_Age_Sex	289
_Result 35-39, Female, Negative	209
HTS_TST_N_DSD_TBC_Age_Sex	4.4
_Result 35-39, Female, Positive	11
HTS_TST_N_DSD_TBC_Age_Sex	222
_Result 35-39, Male, Negative	322
HTS_TST_N_DSD_TBC_Age_Sex	1



_Result 35-39, Male, Positive	
HTS_TST_N_DSD_TBC_Age_Sex	C.F.
_Result 40-49, Female, Negative	65
HTS_TST_N_DSD_TBC_Age_Sex	4
_Result 40-49, Female, Positive	1
HTS_TST_N_DSD_TBC_Age_Sex	66
_Result 40-49, Male, Negative	66
HTS_TST_N_DSD_TBC_Age_Sex	
_Result 40-49, Male, Positive	6
HTS_TST_N_DSD_VCT_Age_Sex	204
_Result 25-29, Female, Negative	381
HTS_TST_N_DSD_VCT_Age_Sex	400
_Result 25-29, Female, Positive	199
HTS_TST_N_DSD_VCT_Age_Sex	4.450
_Result 25-29, Male, Negative	1,453
HTS_TST_N_DSD_VCT_Age_Sex	
_Result 25-29, Male, Positive	283
HTS_TST_N_DSD_VCT_Age_Sex	0.404
_Result 30-34, Female, Negative	3,484
HTS_TST_N_DSD_VCT_Age_Sex	404
_Result 30-34, Female, Positive	431
HTS_TST_N_DSD_VCT_Age_Sex	7 705
_Result 30-34, Male, Negative	7,735
HTS_TST_N_DSD_VCT_Age_Sex	00
_Result 30-34, Male, Positive	92
HTS_TST_N_DSD_VCT_Age_Sex	4.074
_Result 35-39, Female, Negative	4,071
HTS_TST_N_DSD_VCT_Age_Sex	044
_Result 35-39, Female, Positive	211
HTS_TST_N_DSD_VCT_Age_Sex	4.000
_Result 35-39, Male, Negative	1,899
HTS_TST_N_DSD_VCT_Age_Sex	0.5
_Result 35-39, Male, Positive	32
HTS_TST_N_DSD_VCT_Age_Sex	5,765



1	
_Result 40-49, Female, Negative	
HTS_TST_N_DSD_VCT_Age_Sex	1.40
_Result 40-49, Female, Positive	143
HTS_TST_N_DSD_VCT_Age_Sex	0 207
_Result 40-49, Male, Negative	2,327
HTS_TST_N_DSD_VCT_Age_Sex	10
_Result 40-49, Male, Positive	19
HTS_TST_N_DSD_VMMC_Age_S	0.070
ex_Result 25-29, Male, Negative	2,976
Number of people receiving	000
post-GBV care	838
By type of service: Physical and/or	
Emotional Violence (Other	418
Post-GBV Care)	
By type of service: Sexual Violence	420
(Post-Rape Care)	4 20
10-14, Female, Physical and/or	42
Emotional Violence	42
10-14, Female, Sexual Violence	42
(Post-Rape Care)	42
15-19, Female, Physical and/or	168
Emotional Violence	100
15-19, Female, Sexual Violence	168
(Post-Rape Care)	100
20-24, Female, Physical and/or	208
Emotional Violence	200
20-24, Female, Sexual Violence	209
(Post-Rape Care)	209
Number of active beneficiaries	
served by PEPFAR OVC programs	37,107
for children and families affected by	37,107
HIV/AIDS	
Age/Sex: 10-14 Male	3,655
Age/Sex: 15-17 Male	2,789
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive HTS_TST_N_DSD_VMMC_Age_S ex_Result 25-29, Male, Negative Number of people receiving post-GBV care By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) By type of service: Sexual Violence (Post-Rape Care) 10-14, Female, Physical and/or Emotional Violence 10-14, Female, Sexual Violence (Post-Rape Care) 15-19, Female, Physical and/or Emotional Violence 15-19, Female, Physical and/or Emotional Violence 20-24, Female, Physical and/or Emotional Violence (Post-Rape Care) 20-24, Female, Physical and/or Emotional Violence (Post-Rape Care) Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS Age/Sex: 10-14 Male



By: Age/sex: Male 18-24	529
By: Age/sex: Male 25+	1,836
Age/Sex: 10-14 Female	3,944
Age/Sex: 15-17 Female	2,501
By: Age/sex: 18-24 Female	762
By: Age/sex: 25+ Female	4,091
Sum of Age/Sex disaggregates	12,889
	2,024
	14,976
	35,303
	1,804
OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner. Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner. Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by	72 % 26,540 37,107
HIV/AIDS TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period Aggregated Age/Sex: Male 15+	2,024
	By: Age/sex: Male 25+ Age/Sex: 10-14 Female Age/Sex: 15-17 Female By: Age/sex: 18-24 Female By: Age/sex: 25+ Female Sum of Age/Sex disaggregates Age/Sex: <1 Age/Sex: 1-9 Program Completion: Active Program Completion: Graduation OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner. Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner. Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during



	(Numerator: The number of	
	registered new and relapse TB	
	cases with documented	
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	Aggregated Age/Sex: Female 15+	
	(Numerator: The number of	
	registered new and relapse TB	
	cases with documented	838
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	TB_ART_TA Percentage of	
	HIV-positive new and relapsed	. 1
	registered TB cases on ART during	n/a
	TB treatment	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	797
	ART during TB treatment during	
	the reporting period	
	Aggregated Age/Sex: Male 15+	
	(Numerator: The number of	
TB_ART_TA	registered new and relapse TB	
	cases with documented	474
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	Aggregated Age/Sex: Female 15+	
	(Numerator: The number of	
	registered new and relapse TB	
	cases with documented	322
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	1 31 7	



	TB_PREV_DSD TB_PREV_DSD	70 %
	The number of ART patients who	
	completed a course of TB	
	preventive therapy or at least 6	54,626
	months of Isoniazid Preventive	34,020
	Therapy (IPT) during the reporting	
	period	
	The number of ART patients who	
	were newly started on TB	
	preventive therapy (including those	
	who newly started on TB	
	preventive therapy in this reporting	78,036
	period and those who started in the	70,030
	previous reporting period but had	
	not been reported as they did not	
	fulfill the minimum requirements for	
TB_PREV_DSD	the previous reporting period).	
10_1 NEV_000	By Age/Sex (Denominator): <15,	2.264
	Female	2,264
	By Age/Sex (Denominator): <15,	4.040
	Male	1,943
	By Age/Sex (Denominator): 15+,	4E 04E
	Female	45,845
	By Age/Sex (Denominator): 15+,	07.007
	Male	27,987
	By Age/Sex (Numerator): <15,	0.45
	Female	2,151
	By Age/Sex (Numerator): <15,	
	Male	1,849
	By Age/Sex (Numerator): 15+,	
	Female	30,890
	By Age/Sex (Numerator): 15+,	
	Male	19,744
TB_PREV_TA	TB_PREV_TA TB_PREV_TA	70 %
	The number of ART patients who	25,068
	The hamber of Art patiente will	20,000



	completed a course of TB	
	preventive therapy or at least 6	
	months of Isoniazid Preventive	
	Therapy (IPT) during the reporting	
	period	
	The number of ART patients who	
	were newly started on TB	
	preventive therapy (including those	
	who newly started on TB	
	preventive therapy in this reporting	05.040
	period and those who started in the	35,816
	previous reporting period but had	
	not been reported as they did not	
	fulfill the minimum requirements for	
	the previous reporting period).	
	By Age/Sex (Denominator): <15,	050
	Female	850
	By Age/Sex (Denominator): <15,	
	Male	831
	By Age/Sex (Denominator): 15+,	
	Female	21,169
	By Age/Sex (Denominator): 15+,	
	Male	12,965
	By Age/Sex (Numerator): <15,	
	Female	813
	By Age/Sex (Numerator): <15,	
	Male	791
	By Age/Sex (Numerator): 15+,	
	Female	14,542
	By Age/Sex (Numerator): 15+,	
	Male	8,928
	TX_TB_DSD The proportion of	
TX_TB_DSD	ART patients who were screened	0 %
	who are receiving TB treatment	U /0
		07 567
Į	Number of ART patients who were	97,567



	screened for TB at least once	
	during the reporting period	
	Denominator: By Aggregated Age/Sex: <15, Female	3,346
	Denominator: By Aggregated Age/Sex: <15, Male	3,092
	Denominator: By Aggregated Age/Sex:15+, Female	61,879
	Denominator: By Aggregated Age/Sex:15+, Male	29,221
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	9,760
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	9,756
	TX_TB_TA The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	44,760
	Denominator: By Aggregated Age/Sex: <15, Female	925
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	704
	Denominator: By Aggregated Age/Sex: 15+, Female	30,093
	Denominator: By Aggregated Age/Sex: 15+, Male	13,040
	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	4,474



	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	4,239
	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	7,336
	By infants who received a virologic test within 2 months of birth	5,815
	By infants who received their first virologic HIV test between 2 and 12 months of age	1,521
	Sum of Infant Age disaggregates	7,336
	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,234
	By infants who received a virologic test within 2 months of birth	2,641
	By infants who received their first virologic HIV test between 2 and 12 months of age	593
	Sum of Infant Age disaggregates	3,234
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	143,561
	Age/Sex: 15-19 Male	1,579
	Age/Sex: 15-19 Female	2,192



	Age/Sex: <1	207
	Age/Sex: <1-9	3,993
	Age/Sex: 10-14 Male	937
	Age/Sex: 10-14 Female	1,492
	Age/Sex: 20-24 Male	2,908
	Age/Sex: 50+ Male	13,002
	Age/Sex: 20-24 Female	4,915
	Age/Sex: 50+ Female	16,151
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	8,605
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	5,192
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	12,030
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	7,660
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	14,238
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	9,444
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	22,586
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	16,422
	Number of adults and children receiving antiretroviral therapy (ART)	75,384
	Age/Sex: 15-19 Male	720
TX_CURR_TA	Age/Sex: 15-19 Female	1,154
	Sum of Age/Sex disaggregations	1,874
	Age/Sex: <1	99
	Age/Sex: 1-9	2,065
	Age/Sex: 10-14 Male	466



Age/Sex: 20-24 Male 1,483 Age/Sex: 50+ Male 6,840 Age/Sex: 20-24 Female 2,607 Age/Sex: 50+ Female 8,501 TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive Number of adults and children newly enrolled on antiretroviral therapy (ART) By Age/Sex: <1 66 By Age/Sex: 1-9 229 By Age/Sex: 10-14 Male 37			
Age/Sex: 50+ Male 6,840 Age/Sex: 20-24 Female 2,607 Age/Sex: 50+ Female 8,501 TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus		Age/Sex: 10-14 Female	772
Age/Sex: 20-24 Female 2,607 Age/Sex: 50+ Female 8,501 TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive TX_		Age/Sex: 20-24 Male	1,483
Age/Sex: 50+ Female 8,501 TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive Number of adults and children newly enrolled on antiretroviral therapy (ART) By Age/Sex: <1 66 By Age/Sex: <1 66 By Age/Sex: <10-14 Male 37 By Age/Sex: 10-14 Male 37 By Age/Sex: 10-14 Male 37 By Age/Sex: 10-14 Male 368 By Age/Sex: 20-24 Male 868 By Age/Sex: 50+ Male 2,225 By Age/Sex: 10-14 Female 39 By Age/Sex: 10-14 Female 39 By Age/Sex: 15-19 Female 119		Age/Sex: 50+ Male	6,840
TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive 11,887		Age/Sex: 20-24 Female	2,607
atus 25-29, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 36-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive XW_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atu		Age/Sex: 50+ Female	8,501
atus 25-29, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive Number of adults and children newly enrolled on antiretroviral therapy (ART) By Age/Sex: <1 66 By Age/Sex: 1-9 66 By Age/Sex: 10-14 Male 37 TX_NEW_DSD By Age/Sex: 10-14 Male 868 By Age/Sex: 20-24 Male 868 By Age/Sex: 50-4 Male 2,225 By Age/Sex: 10-14 Female 39 By Age/Sex: 15-19 Female 119		_	4,559
atus 30-34, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive Number of adults and children newly enrolled on antiretroviral therapy (ART) By Age/Sex: 1-9 By Age/Sex: 1-9 By Age/Sex: 10-14 Male 37 By Age/Sex: 10-14 Male 37 By Age/Sex: 20-24 Male By Age/Sex: 20-24 Male By Age/Sex: 50- Male By Age/Sex: 10-14 Female 39 By Age/Sex: 10-14 Female 119		•	2,746
atus 30-34, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive Number of adults and children newly enrolled on antiretroviral 17,979 therapy (ART) By Age/Sex: <1 66 By Age/Sex: 1-9 229 By Age/Sex: 10-14 Male 37 TX_NEW_DSD TX_NEW_DSD TX_NEW_DSD By Age/Sex: 10-14 Male 122 By Age/Sex: 20-24 Male 868 By Age/Sex: 50+ Male 2,225 By Age/Sex: 10-14 Female 39 By Age/Sex: 15-19 Female 119		_	6,348
atus 35-39, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive Number of adults and children newly enrolled on antiretroviral therapy (ART) By Age/Sex: <1 66 By Age/Sex: 1-9 229 By Age/Sex: 10-14 Male 37 TX_NEW_DSD TX_NEW_DSD By Age/Sex: 15-19 Male 122 By Age/Sex: 20-24 Male 868 By Age/Sex: 50+ Male 2,225 By Age/Sex: 10-14 Female 39 By Age/Sex: 15-19 Female 119			4,034
atus 35-39, Male, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive Round of adults and children newly enrolled on antiretroviral 17,979 therapy (ART) By Age/Sex: <1 66 By Age/Sex: 1-9 229 By Age/Sex: 10-14 Male 37 TX_NEW_DSD TX_NEW_DSD TX_NEW_DSD TX_NEW_DSD TX_PEW_DSD TX_		_	7,489
atus 40-49, Female, Positive TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive Number of adults and children newly enrolled on antiretroviral 17,979 therapy (ART) By Age/Sex: <1 66 By Age/Sex: 1-9 229 By Age/Sex: 10-14 Male 37 By Age/Sex: 10-14 Male 122 By Age/Sex: 20-24 Male 868 By Age/Sex: 50+ Male 2,225 By Age/Sex: 10-14 Female 39 By Age/Sex: 15-19 Female 119		=	4,971
atus 40-49, Male, Positive Number of adults and children 17,979		_	11,887
newly enrolled on antiretroviral therapy (ART) By Age/Sex: <1 66 By Age/Sex: 1-9 229 By Age/Sex: 10-14 Male 37 By Age/Sex: 15-19 Male 122 By Age/Sex: 20-24 Male 868 By Age/Sex: 50+ Male 2,225 By Age/Sex: 10-14 Female 39 By Age/Sex: 15-19 Female 119		_	8,646
By Age/Sex: 1-9 By Age/Sex: 10-14 Male 37 By Age/Sex: 15-19 Male 122 By Age/Sex: 20-24 Male 868 By Age/Sex: 50+ Male 2,225 By Age/Sex: 10-14 Female 39 By Age/Sex: 15-19 Female 119		newly enrolled on antiretroviral	17,979
By Age/Sex: 10-14 Male 37 By Age/Sex: 15-19 Male 122 By Age/Sex: 20-24 Male 868 By Age/Sex: 50+ Male 2,225 By Age/Sex: 10-14 Female 39 By Age/Sex: 15-19 Female 119		By Age/Sex: <1	66
TX_NEW_DSD By Age/Sex: 15-19 Male 122 By Age/Sex: 20-24 Male 868 By Age/Sex: 50+ Male 2,225 By Age/Sex: 10-14 Female 39 By Age/Sex: 15-19 Female 119		By Age/Sex: 1-9	229
By Age/Sex: 15-19 Male 122 By Age/Sex: 20-24 Male 868 By Age/Sex: 50+ Male 2,225 By Age/Sex: 10-14 Female 39 By Age/Sex: 15-19 Female 119	TX_NEW_DSD	By Age/Sex: 10-14 Male	37
By Age/Sex: 50+ Male 2,225 By Age/Sex: 10-14 Female 39 By Age/Sex: 15-19 Female 119		By Age/Sex: 15-19 Male	122
By Age/Sex: 10-14 Female 39 By Age/Sex: 15-19 Female 119		By Age/Sex: 20-24 Male	868
By Age/Sex: 15-19 Female 119		By Age/Sex: 50+ Male	2,225
		By Age/Sex: 10-14 Female	39
By Age/Sex: 20-24 Female 528		By Age/Sex: 15-19 Female	119
		By Age/Sex: 20-24 Female	528



	By Age/Sex: 50+ Female	2,364
	Pregnancy status	1,081
	Breastfeeding status	12
	FSW	229
	MSM	112
	People in prisons and other enclosed settings	2
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	756
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	1,497
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	758
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	1,762
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	1,026
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	1,671
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	1,741
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	2,148
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,897
	By Age/Sex: <1	24
	By Age/Sex: 1-9	93
	By Age/Sex: 10-14 Male	12
	By Age/Sex: 15-19 Male	57
	By Age/Sex: 20-24 Male	431
	By Age/Sex: 50+ Male	1,109
	By Age/Sex: 10-14 Female	11



	By Age/Sex: 15-19 Female	57
	By Age/Sex: 20-24 Female	261
	By Age/Sex: 50+ Female	1,176
	Sum of Age/Sex disaggregates	3,114
	Pregnancy status	512
	FSW	11
	MSM	8
	TX_NEW_N_TA_Age_Sex_HIVSta tus 25-29, Female, Positive	376
	TX_NEW_N_TA_Age_Sex_HIVSta tus 25-29, Male, Positive	743
	TX_NEW_N_TA_Age_Sex_HIVSta tus 30-34, Female, Positive	376
	TX_NEW_N_TA_Age_Sex_HIVSta tus 30-34, Male, Positive	872
	TX_NEW_N_TA_Age_Sex_HIVSta tus 35-39, Female, Positive	510
	TX_NEW_N_TA_Age_Sex_HIVSta tus 35-39, Male, Positive	829
	TX_NEW_N_TA_Age_Sex_HIVSta tus 40-49, Female, Positive	868
	TX_NEW_N_TA_Age_Sex_HIVSta tus 40-49, Male, Positive	1,064
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records	146,389



	in the past 12 months.	
	Denominator: Indication: Routine	145,205
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	4,951
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	43,118
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	5,766
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	91,375
	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	75,697
	Denominator: Indication: Routine	68,438
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,904
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,577
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	47,373
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	22,855
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	94 %



ε	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	19,319
v p r v	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	20,634
1	Numerator by Status: Pregnant	330
c	Denominator by Status: Pregnant	340
(c t	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on creatment at 12 months after nitiating ART)	436
(c t	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after nitiating ART)	5,486
(c t	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on creatment at 12 months after nitiating ART)	453
(c t	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after nitiating ART)	12,883
(Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated	490



	<u> </u>	
	ART in the 12 months prior to the	
	beginning of the reporting period,	
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	F 000
	beginning of the reporting period,	5,999
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	Aggregated Age/Sex: <15 Female	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	507
	beginning of the reporting period,	507
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	40.000
	beginning of the reporting period,	13,638
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	TX_RET_TA Percent of adults and	
	children known to be alive and on	22.27
	treatment 12 months after initiation	93 %
TX_RET_TA	of antiretroviral therapy	
	Number of adults and children who	
	are still alive and on treatment at	9,467
	12 months after initiating ART	,
	12 months after initiating ART	



Total number of adults and children	
who initiated ART in the 12 months	
prior to the beginning of the	40.000
reporting period, including those	10,223
who have died, those who have	
stopped ART, and those lost to	
follow-up	
Numerator by Status: Pregnant	170
Denominator by Status: Pregnant	203
Aggregated Age/Sex: <15 Male	
(Numerator: Number of adults and	
children who are still alive and on	171
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: 15+ Male	
(Numerator: Number of adults and	
children who are still alive and on	2,802
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: <15 Female	
(Numerator: Number of adults and	
children who are still alive and on	180
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: 15+ Female	
(Numerator: Number of adults and	
children who are still alive and on	6,311
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: <15 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	187
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	



1	
those lost to follow-up)	
Aggregated Age/Sex: 15+ Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	3,178
beginning of the reporting period,	3,170
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: <15 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	000
beginning of the reporting period,	200
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: 15+ Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	0.000
beginning of the reporting period,	6,666
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
6459	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	36,667
9872	Potentia Namibia Recruitment Consultancy	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
9876	Namibia Institute of Pathology	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
9940	Development Aid from People to People, Namibia	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
10181	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	128,206
10389	Management Sciences for	NGO	U.S. Agency for International		



	Health		Development		
10397	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	966,000
10780	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
12752	Ministry of Health and Social Services, Namibia	Government	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
13207	Polytechnic of Namibia	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
13227	ITECH	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration		
13601	Society for Family Health	NGO	U.S. Agency for International Development	GHP-State	1,858,000
	Project HOPE	NGO	U.S. Agency for	GHP-State	2,511,385



		International		
		Dovolonment		
		Development		
		U.S. Department		
		of Health and		
University of		Human		
Namibia	•			
		Prevention		
		U.S. Department		
		of Health and		
University of		Human		
California at San	University	Services/Centers		
Francisco		for Disease		
		Control and		
		Prevention		
		U.S. Department		
		of Health and		
Ministry of Health	Host Country	Human		
and Social	Government	Services/Centers	GHP-State	4,117,000
Services, Namibia	Agency	for Disease		
		Control and		
		Prevention		
		U.S. Department		
		of Health and		
University of		Human		
California at San	University	Services/Centers	GHP-State	350,000
Francisco		for Disease		
		Control and		
		Prevention		
		U.S. Agency for		
Abt Associates		= -		
JHPIEGO	l Iniversity			
51 II 1E 50	Chiversity			
	University of California at San Francisco Ministry of Health and Social Services, Namibia University of California at San Francisco Abt Associates	University of California at San Francisco Ministry of Health and Social Services, Namibia University Government Agency University of California at San Francisco University Francisco Private Contractor	University of Namibia University Services/Centers for Disease Control and Prevention U.S. Department of Health and Human Services/Centers for Disease Control and Prevention U.S. Department of Health and Human University University University University Services/Centers for Disease Control and Prevention U.S. Department of Health and Human Services/Centers for Disease Control and Prevention U.S. Department of Health and Human Services/Centers for Disease Control and Prevention U.S. Department of Health and Human University of California at San Francisco Abt Associates Private Contractor U.S. Agency for International Development U.S. Agency for	University of Namibia University Services/Centers for Disease Control and Prevention U.S. Department of Health and Human California at San Francisco University University University University Services/Centers for Disease Control and Prevention U.S. Department of Health and Human Services/Centers for Disease Control and Prevention U.S. Department of Health and Human Services/Centers for Disease Control and Prevention U.S. Department of Health and Human Services/Centers for Disease Control and Prevention U.S. Department of Health and Human University of California at San Francisco U.S. Department of Health and Human U.S. Agency for International



18088	Catholic Relief	FBO	U.S. Agency for		
			Prevention		
			Control and		
18040	Organization	Agency	for Disease		
		Multi-lateral	Services/Centers	GHP-State	50,000
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Multi laterel	Human		
			of Health and		
			U.S. Department		
18039	TBD	TBD	Redacted	Redacted	Redacted
			Administration		
			Services		
	Washington		Resources and		
18037	University of	University	Services/Health		
	11.2 2		Human		
			of Health and		
			U.S. Department		
			Prevention		
			Control and		
	Medicine		for Disease		
18036		NGO	Services/Centers		
	African Society for		Human		
			of Health and		
			U.S. Department		
			Prevention		
			Control and		
	Washington	,	for Disease		, , , , , , , , , , , , , , , , , , , ,
18035	University of	University	Services/Centers	GHP-State	7,069,605
			Human		
			of Health and		
			U.S. Department		
17002	Carolina	Onversity	Development		
17532	University of North	I Iniversity	International		
			U.S. Agency for		
17551	International, Inc	1100	Development	Or II -State	0,210,107
17531	IntraHealth	NGO	U.S. Agency for International	GHP-State	8,216,107



	Services		International		
			Development		
18126	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	527,200
18354	Potentia Namibia Recruitment Consultancy	Private Contractor	U.S. Department of Health and Human	GHP-State	10,031,200
18355	Development Aid from People to People, Namibia	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,800,000
18356	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,245,648
18357	Namibia Institute of Pathology	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,138,000
18358	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human		



			Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
	UNAIDS - Joint		of Health and		
	United Nations	Multi-lateral	Human		
18359	Programme on	Agency	Services/Centers	GHP-State	50,000
	HIV/AIDS	3 - 1	for Disease		
			Control and		
			Prevention		
			U.S. Department		
	Health Research		of Health and		
	Inc./New York	Other USG	Human		
18360	State Department of Health		Services/Health	GHP-State	200,000
			Resources and		
			Services		
			Administration		
			U.S. Department		
			of Health and		
	Association of		Human		
18362	Public Health	NGO	Services/Centers		
	Laboratories		for Disease		
			Control and		
			Prevention		
18400	TBD	TBD	Redacted	Redacted	Redacted
	Global Health		U.S. Agency for		
18401	Supply Chain	Private Contractor	International	GHP-State	902,894
	Program		Development		
18402	TBD	TBD	Redacted	Redacted	Redacted
	D I		U.S. Agency for		
18404	Population	NGO	International		
	Council		Development		
18420	TBD	TBD	Redacted	Redacted	Redacted
18430	U.S. Department	Implementing	U.S. Department		



	of Health and	Agency	of Health and		
	Human		Human		
	Services/Centers		Services/Centers		
	for Disease		for Disease		
	Control and		Control and		
	Prevention		Prevention		
	(HHS/CDC)				
	Baylor University,		U.S. Agency for		
18608	College of	University	International	GHP-State	167,391
	Medicine		Development		
			U.S. Department		
	Clinical and		of Health and		
	Clinical and		Human		
18611	Laboratory	NGO	Services/Centers		
	Standards		for Disease		
	Institute		Control and		
			Prevention		
			U.S. Agency for		
18612	ICF Macro	Private Contractor	International		
			Development		
18658	TBD	TBD	Redacted	Redacted	Redacted
70228	TBD	TBD	Redacted	Redacted	Redacted
			U.S. Department		
			of Health and		
			Human		
70229	[Placeholder]	TBD	Services/Centers		
			for Disease		
			Control and		
			Prevention		
70230	TBD	TBD	Redacted	Redacted	Redacted
			U.S. Department		
			of Health and		
70231	[Placeholder]	TBD	Human		
			Services/Centers		
			for Disease		



	<u> </u>	1		
			Control and	
			Prevention	
			U.S. Department	
			of Health and	
			Human	
70232	[Placeholder]	TBD	Services/Centers	
			for Disease	
			Control and	
			Prevention	
			U.S. Department	
			of Health and	
			Human	
70233	[Placeholder]	TBD	Services/Centers	
			for Disease	
			Control and	
			Prevention	
			U.S. Department	
			of Health and	
			Human	
70234	[Placeholder]	TBD	Services/Centers	
			for Disease	
			Control and	
			Prevention	
			U.S. Department	
			of Health and	
			Human	
70235	[Placeholder]	TBD	Services/Centers	
			for Disease	
			Control and	
			Prevention	
			U.S. Department	
	CENTRE FOR		of Health and	
70000	SUPPORTING	NOO	Human	
70236	COMMUNITY	NGO	Services/Centers	
	DEVELOPMENT		for Disease	
	INITIATIVES		Control and	



			Prevention	
			U.S. Department	
			of Health and	
			Human	
70237	[Placeholder]	TBD	Services/Centers	
			for Disease	
			Control and	
			Prevention	
			U.S. Department	
			of Health and	
			Human	
70238	[Placeholder]	TBD	Services/Centers	
			for Disease	
			Control and	
			Prevention	
			U.S. Department	
			of Health and	
			Human	
70239	[Placeholder]	TBD	Services/Centers	
			for Disease	
			Control and	
			Prevention	
			U.S. Department	
			of Health and	
			Human	
70240	[Placeholder]	TBD	Services/Centers	
			for Disease	
			Control and	
			Prevention	
			U.S. Department	
			of Health and	
			Human	
70241	[Placeholder]	TBD	Services/Centers	
			for Disease	
			Control and	
			Prevention	



	T	1	T	T	T
70242	[Placeholder]	TBD	U.S. Department of Health and Human Services/Health Resources and Services Administration		
70243	[Placeholder]	TBD	U.S. Department of Health and Human Services/Health Resources and Services Administration		
70244	[Placeholder]	TBD	U.S. Department of Health and Human Services/Health Resources and Services Administration		
70247	TBD	TBD	Redacted	Redacted	Redacted
70248	TBD	TBD	Redacted	Redacted	Redacted
70249	Chemonics. Inc	Private Contractor	U.S. Agency for International Development	GHP-State	1,755,793
70250	Remote Medical International	Private Contractor	U.S. Agency for International Development		
70251	[Placeholder]	TBD	U.S. Agency for International Development		
70252	[Placeholder]	TBD	U.S. Agency for International Development		



70253	[Placeholder]	TBD	U.S. Agency for International Development	
70511	[Placeholder]	TBD	U.S. Department of State/Office of the Global AIDS Coordinator	



Implementing Mechanism(s)

Implementing Mechanism Details

implementing Mechanism Details		
Mechanism ID: 6459	Mechanism Name: Department of State/African Affairs	
Funding Agency: State/AF	Procurement Type: USG Core	
Prime Partner Name: U.S. Department of State		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
BD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 36,667	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 63,333		
Total All Funding Sources and Applied Pipeline Amount: 100,000		
Funding Source Funding Amount		
GHP-State	36,667	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Baagot Goad Information			
Mechanism ID:	6459		
Mechanism Name:	Department of State/African Affairs		
Prime Partner Name:	U.S. Department of State		
Strategic Area	Budget Code Planned Amount		
Care	HBHC	0	
Strategic Area	Budget Code	Planned Amount	



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	36,667
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 9872	Mechanism Name: Cooperative Agreement 1U2GPS002722	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Potentia Namibia Recruitment Consultancy		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
D: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	



(No data provided.)

Budget Code Information	Budget Code Information		
Mechanism ID: 9872			
Mechanism Name:	Cooperative Agreement 1U2GPS002722		
Prime Partner Name:	Potentia Namibia Recruitment Consultancy		
Strategic Area	Budget Code Planned Amount		
Care	HBHC	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

implementing meenament betane		
Mechanism ID: 9876	Mechanism Name: Cooperative Agreement 1U2GPS002058	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Namibia Institute of Pathology		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
BD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

	9876 Cooperative Agreement 1U2GPS002058 Namibia Institute of Pathology	
Strategic Area	Budget Code Planned Amount	
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 9940	Mechanism Name: Cooperative Agreement 1U2GPS0018665166	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Development Aid from People to People, Namibia		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount



Budget Code Information		
Mechanism ID:	9940	
Mechanism Name: Prime Partner Name:	Cooperative Agreement 1U2GPS0018665166 Development Aid from People to People, Namibia	
Strategic Area	Budget Code Planned Amount	
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HMIN	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HVAB	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HVCT	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HVOP	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	IDUP	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	MTCT	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXD	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXS	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	PDTX	0	

(No data provided.)



Mechanism ID: 10181	Mechanism Name: PEACE CORPS NAMIBIA	
Funding Agency: PC	Procurement Type: Cooperative Agreement	
Prime Partner Name: U.S. Peace Corps		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 128,206 Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 128,206			
Funding Source Funding Amount			
GHP-State	128,206		

(No data provided.)

Baagot Goad Illionnation		
Mechanism ID:	10181	
Mechanism Name:	PEACE CORPS NAMIBIA	
Prime Partner Name:	U.S. Peace Corps	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	25,641
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	102,565
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,173
PP_PREV_DSD	Age/sex: 10-14 Male	18
PP_PREV_DSD	Age/sex: 15-19 Male	439
PP_PREV_DSD	Age/sex: 20-24 Male	479
PP_PREV_DSD	Age/sex: 10-14 Female	116
PP_PREV_DSD	Age/sex: 15-19 Female	608
PP_PREV_DSD	Age/sex: 20-24 Female	659
PP_PREV_DSD	Sum of Age/Sex disaggregates	2,319
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	338
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	205
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	360
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	247
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	300
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	251
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	136
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	17



OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,859
OVC_SERV_DSD	Age/Sex: 10-14 Male	300
OVC_SERV_DSD	Age/Sex: 15-17 Male	231
OVC_SERV_DSD	By: Age/sex: Male 18-24	44
OVC_SERV_DSD	By: Age/sex: Male 25+	150
OVC_SERV_DSD	Age/Sex: 10-14 Female	323
OVC_SERV_DSD	Age/Sex: 15-17 Female	206
OVC_SERV_DSD	By: Age/sex: 18-24 Female	63
OVC_SERV_DSD	By: Age/sex: 25+ Female	323
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,060
OVC_SERV_DSD	Age/Sex: <1	145
OVC_SERV_DSD	Age/Sex: 1-9	2,074
OVC_SERV_DSD	Program Completion: Active	3,713
OVC_SERV_DSD	Program Completion: Graduation	146

Mechanism ID: 10389	Mechanism Name: Systems to Improve Access to Pharmaceuticals and Services	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Management Sciences for Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	



Budget Code Information		
Mechanism ID: 10389		
Mechanism Name: Systems to Improve Access to Pharmaceuticals and Services		
Prime Partner Name:	Management Sciences for Health	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)



Mechanism ID: 10397	Mechanism Name: Challenge TB Fund	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: KNCV Tuberculosis Foundation		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 966,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 966,000		
Funding Source Funding Amount		
GHP-State	966,000	

(No data provided.)

budget code information	T		
Mechanism ID:	10397		
Mechanism Name:	Challenge TB Fund		
Prime Partner Name:	KNCV Tuberculosis Foundation	KNCV Tuberculosis Foundation	
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	966,000	



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10780	Mechanism Name: Cooperative Agreement 1U58PS001452	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Washington		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)



Budget Code Information		
Mechanism ID: 10780		
Mechanism Name: Cooperative Agreement 1U58PS001452		
Prime Partner Name: University of Washington		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 12752	Mechanism Name: Cooperative Agreement 1U2GPS003014
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Ministry of Health and Social Services, Namibia		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No Managing Agency:		

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Mechanism ID:	:12752	
Mechanism Name:	Cooperative Agreement 1U2GPS003014	
Prime Partner Name:	Ministry of Health and Social Services, Namibia	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	o



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

mpionioning moonament betane		
Mechanism ID: 13207	Mechanism Name: Cooperative Agreement 1U2GPS002902	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Polytechnic of Namibia		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)



Budget Code Information		
Mechanism Name:	Mechanism ID: 13207 Mechanism Name: Cooperative Agreement 1U2GPS002902 Prime Partner Name: Polytechnic of Namibia	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 13227	Mechanism Name: I-TECH: Support to MOHSS National Health Training Center (NHTC)
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: ITECH	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	I-TECH: Support to MOHSS National Health Training Center (NHTC)		
Strategic Area	Budget Code Planned Amount		
Care	HBHC	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13601	Mechanism Name: Strengthening HIV Prevention for Key Populations	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Society for Family He	ealth	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
BD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A	4	
G2G: No	Managing Agency:	

Total All Funding Sources: 1,858,000	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 116,000			
Total All Funding Sources and Applied Pipeline Amount: 1,974,000			
Funding Source Funding Amount			
GHP-State	1,858,000		

Cross-Cutting Budget Attribution(s)



Budget Code Information	Budget Code Information		
Mechanism ID: Mechanism Name: Prime Partner Name:	e: Strengthening HIV Prevention for Key Populations		
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	400,000	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	CIRC	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HMBL	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HMIN	0	
Strategic Area	Budget Code	Planned Amount	



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	364,500
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,093,500
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	638
PrEP_NEW_DSD	Female 15-19	145
PrEP_NEW_DSD	Female 20-24	492
PrEP_NEW_DSD	FSW	240



KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	14,946
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,915
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	45
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,986
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,204
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	17
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	5



	50+, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	403
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	451
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	481
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	553
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	139
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	142
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	117
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	133
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male,	24



	Positive	
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	116
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	184
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	194
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	178
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	5
HTC_TST_DSD	By Key Population: FSW, Negative	659
HTC_TST_DSD	By Key Population: FSW, Positive	64
HTC_TST_DSD	By Key Population: MSM, Negative	861
HTC_TST_DSD	By Key Population: MSM, Positive	48
HTC_TST_DSD	By Key Population: TG, Negative	6
HTC_TST_DSD	By Key Population: TG, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	63
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	46
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	81
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24,	11



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	63
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	22
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39,	1



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	84
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	114
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49,	16



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	479
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	493
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	540
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	521
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	424
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	420
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	266
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49,	212



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	1,044
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	304
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	245
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	271
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	225
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49,	2



	Male, Positive	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,308
TX_CURR_DSD	Age/Sex: 15-19 Male	28
TX_CURR_DSD	Age/Sex: 15-19 Female	37
TX_CURR_DSD	Sum of age/sex disaggregates	65
TX_CURR_DSD	Age/Sex: 20-24 Male	50
TX_CURR_DSD	Age/Sex: 50+ Male	219
TX_CURR_DSD	Age/Sex: 20-24 Female	82
TX_CURR_DSD	Age/Sex: 50+ Female	272
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	145
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	86
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	203
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	130
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	239
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	159
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	380
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	278
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	856
TX_NEW_DSD	By Age/Sex: 15-19 Male	6
TX_NEW_DSD	By Age/Sex: 20-24 Male	42
TX_NEW_DSD	By Age/Sex: 50+ Male	119
TX_NEW_DSD	By Age/Sex: 15-19 Female	6
TX_NEW_DSD	By Age/Sex: 20-24 Female	25



TX_NEW_DSD	By Age/Sex: 50+ Female	95
TX_NEW_DSD	Sum of Age/Sex disaggregates	293
TX_NEW_DSD	Pregnancy status	25
TX_NEW_DSD	FSW	224
TX_NEW_DSD	MSM	107
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	37
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	71
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	37
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	86
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	50
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	82
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	84
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	116
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,383
TX_PVLS_DSD	Denominator: Indication: Routine	2,383
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	84
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	792
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	86
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,421
TX_RET_DSD	Number of adults and children who are still alive and on	614



	to a store and at 40 manufles a first to 10 miles APT	
	treatment at 12 months after initiating ART	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	876
TX_RET_DSD	Numerator by Status: Pregnant	7
TX_RET_DSD	Denominator by Status: Pregnant	12
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	203
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	411
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	277
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	599
HTS_SELF_DSD	HTS_SELF_N_DSD	13,503
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	654
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	600
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1,062
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	1,200
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	600



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	1,692
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	1,200
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	871
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	750
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	1,500
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	2,400
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	523
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	600
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	1,350
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	13,503

Implementing Mechanism Details

Mechanism ID: 13752	Mechanism Name: Adherence & Retention Project	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Project HOPE		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 2,511,385	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 2,511,385		
Funding Source	Funding Amount	



(-HP-S1314	2,511,385
	, ,

Cross-Cutting Budget Attribution(s)

Water	50,000	

Budget Code Information		
Mechanism ID	: 13752	
Mechanism Name	Adherence & Retention Project	
Prime Partner Name	: Project HOPE	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	1,880,894
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	220,676
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	409,815
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Indicator Number	Label	2019
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	21,194
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	468
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	70
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	311
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	625
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	468
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	154
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	103
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	291
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male,	408



	Negative	
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	50
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	231
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	582
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	526
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	465
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	632
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	545
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	794
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	80
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	632
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24,	97



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	530
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	43
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	380
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	364
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	52
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	85
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	677
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	987
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	78
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	259
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	115
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	208
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	85
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49,	310



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	208
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	253
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	670
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	128
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	723
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	90
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	827
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	320
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	460
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	118
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	325
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49,	180



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	757
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	175
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	465
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	85
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	993
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	465
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	177
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	817
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	231
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	22,878



OVC_SERV_DSD	Age/Sex: 10-14 Male	2,339
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,791
OVC_SERV_DSD	By: Age/sex: Male 18-24	344
OVC_SERV_DSD	By: Age/sex: Male 25+	1,169
OVC_SERV_DSD	Age/Sex: 10-14 Female	2,520
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,609
OVC_SERV_DSD	By: Age/sex: 18-24 Female	493
OVC_SERV_DSD	By: Age/sex: 25+ Female	2,558
OVC_SERV_DSD	Sum of Age/Sex disaggregates	8,259
OVC_SERV_DSD	Age/Sex: <1	1,196
OVC_SERV_DSD	Age/Sex: 1-9	8,859
OVC_SERV_DSD	Program Completion: Active	21,738
OVC_SERV_DSD	Program Completion: Graduation	1,140
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	18,244
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	22,878

Implementing Mechanism Details

Mechanism ID: 14390	Mechanism Name: Cooperative Agreement U2GGH001182	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Namibia		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No Managing Agency:		

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
i anang course	i anang Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information		
Mechanism ID: Mechanism Name: Prime Partner Name:	Cooperative Agreement U2GGH001182	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

implementing mechanism betails		
Mechanism ID: 14391	Mechanism Name: University of California-San Francisco	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of California at San Francisco		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Daaget Gode information		
Mechanism ID:	14391	
Mechanism Name:	University of California-San Francisco	
Prime Partner Name:	University of California at San Francisco	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code Planned Amount	



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount	
Prevention	IDUP	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	MTCT	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXD	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXS	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	PDTX	0	

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16756	Mechanism Name: Improving the Quality of Namibia"s Essential Health Services and Systems (IQ-NEHSS)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Ministry of Health and Social Services, Namibia		
Agreement Start Date: Redacted Agreement End Date: Redacted		
BD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 4,117,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,117,000	



Funding Source	Funding Amount
GHP-State	4,117,000

Cross-Cutting Budget Attribution(s)

Adolescent Girls and Young Women (AGYW)	420,000
Addiescent dins and roung women (Ad I W)	1420,000

Mechanism ID: Mechanism Name: Prime Partner Name: Mechanism Name: Prime Partner Name: Ministry of Health and Social Services, Namibia		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	127,140
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	255,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	117,724
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	582,000
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	408,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	205,200
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	360,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	574,232
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	110,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	110,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	938,364
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	329,340



Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,591
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,813
PMTCT_ART_DSD	New on ART	397
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,194
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,553
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	24,275
PMTCT_ART_TA	New on ART	880
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	2,673
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,813
PMTCT_STAT_DSD	Number of new ANC and L&D clients	9,277
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,409
PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,584
PMTCT_STAT_DSD	By Number of known positives: 15-19	34
PMTCT_STAT_DSD	By Number of known positives: 20-24	125
PMTCT_STAT_DSD	By Number of new positives: 15-19	65
PMTCT_STAT_DSD	By Number of new positives: 20-24	125
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,234
PMTCT_STAT_DSD	By Number of new negative: 20-24	2,197



PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,330
PMTCT_STAT_DSD	By Age (Numerator): 20-24	2,447
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	2,150
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	1,659
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	1,033
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	442
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	255
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	1,636
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	136
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	333
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	1,180
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	75
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	334
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	618
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	38
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	146
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	274
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	8
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	2,035
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	1,588
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	989



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	431
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	24,275
PMTCT_STAT_TA	Number of new ANC and L&D clients	25,551
PMTCT_STAT_TA	By Age (Denominator): 15-19	2,504
PMTCT_STAT_TA	By Age (Denominator): 20-24	7,599
PMTCT_STAT_TA	By known positives: 15-19	37
PMTCT_STAT_TA	By known positives: 20-24	160
PMTCT_STAT_TA	By new positives: 15-19	168
PMTCT_STAT_TA	By new positives: 20-24	157
PMTCT_STAT_TA	By new negatives: 15-19	2,103
PMTCT_STAT_TA	By new negatives: 20-24	6,662
PMTCT_STAT_TA	By Age (Numerator): : 15-19	2,310
PMTCT_STAT_TA	By Age (Numerator): 20-24	6,974
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	6,703
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	5,014
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	2,674
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	1,057
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,317
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	5,364
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	277
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	486
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	3,900
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	193
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	527



PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,777
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	149
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	264
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	726
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	3
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	6,953
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	4,582
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	2,459
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	995
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	54,524
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	80
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	252
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	350
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24,	215



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	512
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	450
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	453
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	292
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	310
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	182
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	727
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,014
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	94
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	581
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,456



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,307
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	63
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,161
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	111
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,236
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	90
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	46



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	213
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	296
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	170
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	422
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	382
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	339
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,547
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	108
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	2,827
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	181
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	158
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	700



	<u></u>	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	968
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	85
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	573
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,384
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	1,234
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,234
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	505
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	126
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	61
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	339
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34,	94



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	722
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	339
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	126
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	592
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	172
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	158
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	92
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	402
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	875
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34,	23



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	418
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	660
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	213
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	436
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	102
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,160
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	175
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	2,467
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,160
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39,	72



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	436
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	2,031
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	581
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	2,142
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	151
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,588
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	816
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	451
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	71
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	81
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	63
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39,	81



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	92
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	411
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	85
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,118
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	148
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	2,362
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	1,100
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	418
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1,789
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49,	42



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	554
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	61,477
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	73
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	46
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	277
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	53
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	307
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	26
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	271
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	45
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	449
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	38
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	342



HTC_TST_TA Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) Inpatient: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) Inpatient: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) Inpatient: <1, Negative 19 HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Negative HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Positive 4 HTC_TST_TA Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative Service Delivery Point (Facility) Other PITC: 15-19,	
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) Inpatient: <1, Negative 15 HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Negative HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Positive HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Positive 4 HTC_TST_TA Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 15	
HTC_TST_TA Positive HTC_TST_TA Service Delivery Point (Facility) Inpatient: <1, Negative 19 HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Negative 200 HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Positive 4 HTC_TST_TA Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 15	
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Negative 200 HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Positive 4 HTC_TST_TA Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 152	
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Positive 4 Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 152	
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 152	
HTC_TST_TA Female, Negative Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 152	
Male, Negative 152	
Service Delivery Point (Facility) Other PITC: 15-19	
HTC_TST_TA Service Delivery Form (Facility) Other FTTC: 13-19, Female, Negative 833	
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	•
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 753	
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 83	
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 1,691	
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	,
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 75	
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 1,303	
HTC_TST_TA Service Delivery Point (Facility) Other PITC: 50+, Male, 35	.



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	82
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	936
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	45
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	27
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	90
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	63
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	36
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female,	2



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	64
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	27
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	44
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	361
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	79
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	497
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	97
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	311
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	80
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	738
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	59
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	654
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	76
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	582
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	27
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	1,554
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	76
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	3,730



HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	216
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	258
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	139
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	688
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	789
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	60
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	733
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	48
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,173
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	42
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	889
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	40
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	867
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	42
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	423
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	17



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	8
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	88
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	229
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	108
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	588
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	156
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	1,262
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	37
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	594
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	89
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	237
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	19
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	1,019
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	59
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	313
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	86
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	58



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	112
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	77
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	422
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	109
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	790
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	28
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	335
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	65
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	154
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	16
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	518
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	39
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	182
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	42
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	84
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	533



HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	130
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,313
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	224
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	2,803
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	37
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,423
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	95
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	567
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	2,353
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	61
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	754
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	3,447
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	225
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,465
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	191



HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,114
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	93
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	391
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	46
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	73
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	81
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	81
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	64
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	81
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	90
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	17



	·	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	17
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	206
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Positive	65
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	331
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Positive	87
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	1,056
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Positive	101
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	2,036
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Positive	35
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	944
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Positive	73
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	431
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Positive	25
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	1,384
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Positive	39



HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	542
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Positive	17
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,614
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,696
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	106
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	850
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	72
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	586
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	110
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	897
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	76
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	614
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,985
TB_STAT_TA	Total number of registered new and relapsed TB cases,	2,090



	during the reporting period.	
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	203
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	278
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	691
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	918
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	224
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	901
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	183
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	677
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	574
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	370
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	204



	T	
	TB treatment during the reporting period)	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	797
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	474
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	322
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,501
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,161
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	340
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,501
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,535
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,894
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	641
PMTCT_EID_TA	Sum of Infant Age disaggregates	3,535
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	26,934
TX_CURR_DSD	Age/Sex: 15-19 Male	269
TX_CURR_DSD	Age/Sex: 15-19 Female	406
TX_CURR_DSD	Sum of age/sex disaggregates	675
TX_CURR_DSD	Age/Sex: <1	44
TX_CURR_DSD	Age/Sex: <1-9	881
TX_CURR_DSD	Age/Sex: 10-14 Male	207



TX_CURR_DSD	Age/Sex: 10-14 Female	328
TX_CURR_DSD	Age/Sex: 20-24 Male	537
TX_CURR_DSD	Age/Sex: 50+ Male	2,420
TX_CURR_DSD	Age/Sex: 20-24 Female	922
TX_CURR_DSD	Age/Sex: 50+ Female	3,007
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,612
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	968
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,238
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,426
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2,650
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,757
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	4,202
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	3,057
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	75,384
TX_CURR_TA	Age/Sex: 15-19 Male	720
TX_CURR_TA	Age/Sex: 15-19 Female	1,154
TX_CURR_TA	Sum of Age/Sex disaggregations	1,874
TX_CURR_TA	Age/Sex: <1	99
TX_CURR_TA	Age/Sex: 1-9	2,065
TX_CURR_TA	Age/Sex: 10-14 Male	466
TX_CURR_TA	Age/Sex: 10-14 Female	772
TX_CURR_TA	Age/Sex: 20-24 Male	1,483
TX_CURR_TA	Age/Sex: 50+ Male	6,840
TX_CURR_TA	Age/Sex: 20-24 Female	2,607



TX_CURR_TA	Age/Sex: 50+ Female	8,501
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	4,559
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	2,746
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	6,348
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	4,034
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	7,489
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	4,971
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	11,887
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	8,646
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,409
TX_NEW_DSD	By Age/Sex: <1	17
TX_NEW_DSD	By Age/Sex: 1-9	60
TX_NEW_DSD	By Age/Sex: 10-14 Male	8
TX_NEW_DSD	By Age/Sex: 15-19 Male	35
TX_NEW_DSD	By Age/Sex: 20-24 Male	260
TX_NEW_DSD	By Age/Sex: 50+ Male	673
TX_NEW_DSD	By Age/Sex: 10-14 Female	8
TX_NEW_DSD	By Age/Sex: 15-19 Female	35
TX_NEW_DSD	By Age/Sex: 20-24 Female	160
TX_NEW_DSD	By Age/Sex: 50+ Female	714
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,893
TX_NEW_DSD	Pregnancy status	258
TX_NEW_DSD	FSW	5
TX_NEW_DSD	MSM	4



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	227
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	227
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	531
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	309
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	504
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	525
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	648
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,897
TX_NEW_TA	By Age/Sex: <1	24
TX_NEW_TA	By Age/Sex: 1-9	93
TX_NEW_TA	By Age/Sex: 10-14 Male	12
TX_NEW_TA	By Age/Sex: 15-19 Male	57
TX_NEW_TA	By Age/Sex: 20-24 Male	431
TX_NEW_TA	By Age/Sex: 50+ Male	1,109
TX_NEW_TA	By Age/Sex: 10-14 Female	11
TX_NEW_TA	By Age/Sex: 15-19 Female	57
TX_NEW_TA	By Age/Sex: 20-24 Female	261
TX_NEW_TA	By Age/Sex: 50+ Female	1,176
TX_NEW_TA	Sum of Age/Sex disaggregates	3,114
TX_NEW_TA	Pregnancy status	525
TX_NEW_TA	FSW	11
TX_NEW_TA	MSM	8
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female,	376



	Positive	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	743
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	376
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	872
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	510
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	829
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	868
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	1,064
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	27,778
TX_PVLS_DSD	Denominator: Indication: Routine	27,778
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,079
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	7,580
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,233
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	17,886
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	75,697
TX_PVLS_TA	Denominator: Indication: Routine	75,697
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,904
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15	2,577



	Male Routine	
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	47,373
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	22,855
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,523
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	
TX_RET_DSD	Numerator by Status: Pregnant	23
TX_RET_DSD	Denominator by Status: Pregnant	41
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	86
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,229
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	89
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,125
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	99
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,353



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	102
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,365
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,467
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,223
TX_RET_TA	Numerator by Status: Pregnant	197
TX_RET_TA	Denominator by Status: Pregnant	234
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	171
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,802
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	180
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,311
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	187



TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,178
Aggregated Age/Sex: <15 Female (Denominator number of adults and children who initiated ART TX_RET_TA 12 months prior to the beginning of the reporting including those who have died, those who have stopped ART, and those lost to follow-up)		200
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,666
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	895
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	821
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1,453
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	1,642
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	821
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	2,315
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	1,642
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	1,193
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	1,026
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	2,052



	The state of the s	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	3,283
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	716
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	821
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	1,847
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	9,166
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	13,094
TB_PREV_DSD By Age/Sex (Denominator): <15, Female		348
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	345
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	7,765
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	4,638
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	330
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	330
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	5,261
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	3,249
The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period		25,068
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period	35,816



	and those who started in the previous reporting period	
	but had not been reported as they did not fulfill the minimum requirements for the previous reporting	
	period).	
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	850
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	831
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	21,169
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	12,965
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	813
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	791
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	14,542
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	8,928
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	16,368
TX_TB_DSD		
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	307
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	11,157
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	4,516
	Denominator: Number of ART patients who had a	
TX_TB_DSD	specimen sent for bacteriologic diagnosis of active TB disease	1,637
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,637
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	44,760
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	925
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	704
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	30,093
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	13,040
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	4,474
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of	4,474



	Specimen Sent]: Gene Xpert MTB / R if Assay	

Implementing Mechanism Details

Mechanism ID: 16771	Mechanism Name: Namibia Mechanism for Public Health Assistance, Capacity, and Technical Support (NAM-PHACTS)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of California at San Francisco		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 350,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pip	peline Amount: 350,000	
Funding Source	Funding Amount	
GHP-State	350,000	

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	100,000
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	100,000
Focus Area:	Collection and use of strategic information

Mechanism ID:	16771
Mechanism Name:	Namibia Mechanism for Public Health Assistance, Capacity, and
Prime Partner Name:	Technical Support (NAM-PHACTS)



	University of California at San Francisco	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	200,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	150,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16829	Mechanism Name: Health Financing and Governance
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	2G: No Managing Agency:		
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source Funding Amount			

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code information		
Mechanism ID: Mechanism Name: Prime Partner Name:	Health Financing and Governance	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17529	Mechanism Name: Maternal and Child Survival Program	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: JHPIEGO		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

zaaget eeur mieniaanen	
Mechanism ID:	17529
Mechanism Name:	Maternal and Child Survival Program
Prime Partner Name:	JHPIEGO



Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17531	Mechanism Name: USAID HIV Clinical Services Technical Assistance Project	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: IntraHealth International, Inc		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Total All Funding Sources: 8,216,107	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 325,000	
Total All Funding Sources and Applied Pipeline	Amount: 8,541,107
Funding Source	Funding Amount
GHP-State	8,216,107

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code information		
	17531 USAID HIV Clinical Services Technical Assistance Project IntraHealth International, Inc	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	1,021,321
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	570,722
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	5,864,989



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	759,075

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,965
PMTCT_ART_DSD	(MTCT) during pregnancy Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,773
PMTCT_ART_DSD	New on ART	612
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,353
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,773
PMTCT_STAT_DSD	Number of new ANC and L&D clients	19,756
PMTCT_STAT_DSD	By Age (Denominator): 10-14	3
PMTCT_STAT_DSD	By Age (Denominator): <15-19	3,011
PMTCT_STAT_DSD	By Age (Denominator): 20-24	5,410
PMTCT_STAT_DSD	By Age (Denominator): 50+	15
PMTCT_STAT_DSD	By Number of known positives: 15-19	52
PMTCT_STAT_DSD	By Number of known positives: 20-24	250
PMTCT_STAT_DSD	By Number of known positives: 50+	2
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	87
PMTCT_STAT_DSD	By Number of new positives: 20-24	202
PMTCT_STAT_DSD	By Number of new negative: 10-14	2
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,730
PMTCT_STAT_DSD	By Number of new negative: 20-24	4,687



By Age (Numerator): 10-14	3
By Age (Numerator): 15-19	2,860
By Age (Numerator): 20-24	5,121
By Age (Numerator): 50+	2
PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	4,402
PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	3,558
PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,314
PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	1,043
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	422
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	3,877
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	239
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	690
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	2,404
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	113
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	701
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,301
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	54
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	340
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	607
PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	4,544
PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	3,206
PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2,059
	By Age (Numerator): 15-19 By Age (Numerator): 20-24 By Age (Numerator): 50+ PMTCT_STAT_D_DSD_Age_Sex 25-29, Female PMTCT_STAT_D_DSD_Age_Sex 30-34, Female PMTCT_STAT_D_DSD_Age_Sex 30-34, Female PMTCT_STAT_D_DSD_Age_Sex 35-39, Female PMTCT_STAT_D_DSD_Age_Sex 40-49, Female PMTCT_STAT_D_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative PMTCT_STAT_N_DSD_Age_Sex_Sex_Sex_Sex_Sex_Sex_Sex_Sex_Sex_Se



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	943
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,086
PrEP_NEW_DSD	Female 15-19	341
PrEP_NEW_DSD	Female 20-24	748
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	102,304
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	151
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	93
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	491
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	673
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	414
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	105
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	970
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female,	863



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	103
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	858
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	49
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	556
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	598
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	350
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,324
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,850
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	164
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,058
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	122
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,642
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	88
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	2,381
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	116
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	2,116



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	209
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	2,362
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	83
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	114
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	1



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	56
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	463
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	133
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	647
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	115
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	369
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	101
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	924
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	75
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	831
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	101
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	738
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	38
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	54
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	7



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	3,430
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	89
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	5,487
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	155
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	246
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	154
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,287
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,769
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	158
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,060
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	92
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	2,547
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	2,277
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	2,273
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	925



	<u> </u>	T
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	113
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	279
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	128
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	742
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	181
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,573
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	742
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	279
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	1,295
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	369
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	107
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29,	287



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	170
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	771
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	297
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,650
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	796
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	118
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	323
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	1,259
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	413
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	794
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	183
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34,	2,116



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	324
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	4,498
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	2,116
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	128
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	794
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	3,705
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,055
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	4,034
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	127
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,992
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,557
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	870
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49,	32



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	90
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	103
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	103
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	77
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	103
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	96
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29,	759



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	159
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	2,031
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	272
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	4,344
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	2,068
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	104
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	819
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	3,308
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,059
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	1
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,590
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,676
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	73



TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	733
TB_STAT_DSD	documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	63
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	721
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	85
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	756
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	87
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	748
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	565
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	313
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	252
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,215
PMTCT_EID_DSD	By infants who received a virologic test within 2 months	2,558



	of birth	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	657
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,215
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	56,714
TX_CURR_DSD	Age/Sex: 15-19 Male	654
TX_CURR_DSD	Age/Sex: 15-19 Female	893
TX_CURR_DSD	Sum of age/sex disaggregates	1,547
TX_CURR_DSD	Age/Sex: <1	95
TX_CURR_DSD	Age/Sex: <1-9	1,903
TX_CURR_DSD	Age/Sex: 10-14 Male	441
TX_CURR_DSD	Age/Sex: 10-14 Female	717
TX_CURR_DSD	Age/Sex: 20-24 Male	1,170
TX_CURR_DSD	Age/Sex: 50+ Male	5,090
TX_CURR_DSD	Age/Sex: 20-24 Female	1,879
TX_CURR_DSD	Age/Sex: 50+ Female	6,325
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,289
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,021
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	4,706
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,994
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	5,575
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,695
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	8,840
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	6,427



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	7,440
TX_NEW_DSD	By Age/Sex: <1	30
TX_NEW_DSD	By Age/Sex: 1-9	106
TX_NEW_DSD	By Age/Sex: 10-14 Male	19
TX_NEW_DSD	By Age/Sex: 15-19 Male	52
TX_NEW_DSD	By Age/Sex: 20-24 Male	358
TX_NEW_DSD	By Age/Sex: 50+ Male	920
TX_NEW_DSD	By Age/Sex: 10-14 Female	19
TX_NEW_DSD	By Age/Sex: 15-19 Female	52
TX_NEW_DSD	By Age/Sex: 20-24 Female	220
TX_NEW_DSD	By Age/Sex: 50+ Female	1,015
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,655
TX_NEW_DSD	Pregnancy status	540
TX_NEW_DSD	Breastfeeding status	12
TX_NEW_DSD	People in prisons and other enclosed settings	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	314
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	615
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	305
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	707
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	420
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	681
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	718
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	889
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral	56,783



	load result documented in the patient medical record	
	and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Denominator: Indication: Routine	56,783
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,046
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	15,682
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,413
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	36,642
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,949
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,306
TX_RET_DSD	Numerator by Status: Pregnant	123
TX_RET_DSD	Denominator by Status: Pregnant	109
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	168
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,151
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	176
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,432
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	176



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,289
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	182
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,659
HTS_SELF_DSD	HTS_SELF_N_DSD	2,143
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	229
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	210
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	377
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	420
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	210
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	593
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	420
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	306
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39,	262



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	525
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	840
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	183
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	210
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	472
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	2,143
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	24,777
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	35,395
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	986
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,008
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	21,116
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	12,288
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	940
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	982
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	13,967
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	8,893
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	44,244
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,012



TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,782
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	28,390
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	12,047
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	4,428
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	4,428

Implementing Mechanism Details

promoning moonamen zotano		
Mechanism ID: 17532	Mechanism Name: Measure Evaluation Phase 4	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of North Carolina		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipe	line Amount: 0
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

_		
	Mechanism ID:	17532
	Mechanism Name:	Measure Evaluation Phase 4
	Prime Partner Name:	University of North Carolina



Strategic Area	Budget Code	Planned Amount
-	-	
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HVOP	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	IDUP	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	MTCT	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXD	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXS	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	PDTX	0	

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18035	Mechanism Name: Namibia Mechanism for Public Health Assistance, Capacity, and Technical Support (NAM-PHACTS)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Washington		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Total All Funding Sources: 7,069,605	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 7,069,605			
Funding Source Funding Amount			
GHP-State	7,069,605		

Cross-Cutting Budget Attribution(s)

Adolescent Girls and Young Women (AGYW)	3,250,000

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	Namibia Mechanism for Public Health Assistance, Capacity, and Technical Support (NAM-PHACTS)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	70,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	24,151
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	50,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	2,423,171
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	787,500
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	84,349
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	2,462,500
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	102,481
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	1,005,073
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	60,380

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,777
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,695
PMTCT_ART_DSD	New on ART	781
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,996
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,695
PMTCT_STAT_DSD	Number of new ANC and L&D clients	20,737
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,937
PMTCT_STAT_DSD	By Age (Denominator): 20-24	6,027
PMTCT_STAT_DSD	By Number of known positives: 15-19	7
PMTCT_STAT_DSD	By Number of known positives: 20-24	265
PMTCT_STAT_DSD	By Number of new positives: 15-19	107
PMTCT_STAT_DSD	By Number of new positives: 20-24	176
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,766
PMTCT_STAT_DSD	By Number of new negative: 20-24	5,207
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,884
PMTCT_STAT_DSD	By Age (Numerator): 20-24	5,647
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	5,168
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	3,880



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,035
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	690
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	710
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	4,236
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	205
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	671
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	2,763
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	175
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	350
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,374
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	90
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	151
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	419
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	4
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	5,153
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	3,611
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	1,826
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	578
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	11,615
VMMC_CIRC_DSD	By Age: 15-19	7,091



VMMC_CIRC_DSD	By Age: 20-24	3,026
VMMC_CIRC_DSD	By Age: 25-29	1,498
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	10,117
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	11,615
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	6,986
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,868
PrEP_NEW_DSD	Female 15-19	443
PrEP_NEW_DSD	Female 20-24	1,425
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	1,868
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	16,160
PP_PREV_DSD	Age/sex: 10-14 Female	3,660
PP_PREV_DSD	Age/sex: 15-19 Female	6,301
PP_PREV_DSD	Age/sex: 20-24 Female	6,199
PP_PREV_DSD	Sum of Age/Sex disaggregates	16,160
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	68,008
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	70
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	15



HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Negative HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Negative HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Negative Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Service Delivery Point (Facility) Inpatient: 50+, Male,	
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Negative HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male, Service Delivery Point (Facility) Inpatient: 50+, Male,	
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Negative Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male.	
HTC_TST_DSD Positive Service Delivery Point (Facility) Inpatient: 50+, Female, Negative HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male,	
HTC_TST_DSD Negative Negative Service Delivery Point (Facility) Inpatient: 50+, Female, Positive Service Delivery Point (Facility) Inpatient: 50+, Male,	
Positive 1 Service Delivery Point (Facility) Inpatient: 50+, Male.	
Service Delivery Point (Facility) Inpatient: 50+. Male.	
HTC_TST_DSD Negative 149	
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: <1, Negative 14	
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 1-9, Negative 94	
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 1-9, Positive 4	
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 128	
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 79	
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 1,047	
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 7	
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 1,324	
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, 112	



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,592
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	122
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,531
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	80
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,658
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,617
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	447
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female,	6



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	117
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	82
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	46
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	82
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	1,683
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	757
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	214
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	264
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male,	41



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	336
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	531
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	366
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	333
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	2,669
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	128
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	5,517
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	205
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	209
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	196
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	166
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	105
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female,	582



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	430
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	277
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	211
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	69
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	368
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	71
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	959
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	27



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	421
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	264
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	638
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	336
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	163
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	135
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	636
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	507



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	379
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	360
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	340
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	263
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	125
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	997
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	166
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,580
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	218
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	4,377
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	2,536
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	124



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,247
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	3,131
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,527
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	5,427
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	194
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	3,754
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	147
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,820
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	450
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	94
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	104



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	82
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	117
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	234
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	212
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	23



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	149
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	622
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	698
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	530
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	475
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	568
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	553
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,353
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,477
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	88
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of	1,320



	<u> </u>	
	registered new and relapsed TB cases with	
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	94
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	851
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	103
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	1,396
	during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	102
	during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	876
	during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	400
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence	200
	(Other Post-GBV Care)	
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	200
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	20
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	20
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	80
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	80
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	100
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	100
	The number of registered new and relapse TB cases	
TB_ART_DSD	with documented HIV-positive status who are on ART	885
	during TB treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The	503



	number of registered new and relapse TB cases with	
	documented HIV-positive status who are on ART during	
	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	382
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,620
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,096
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	524
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,620
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	54,894
TX_CURR_DSD	Age/Sex: 15-19 Male	600
TX_CURR_DSD	Age/Sex: 15-19 Female	813
TX_CURR_DSD	Sum of age/sex disaggregates	1,413
TX_CURR_DSD	Age/Sex: <1	66
TX_CURR_DSD	Age/Sex: <1-9	1,174
TX_CURR_DSD	Age/Sex: 10-14 Male	281
TX_CURR_DSD	Age/Sex: 10-14 Female	434
TX_CURR_DSD	Age/Sex: 20-24 Male	1,094
TX_CURR_DSD	Age/Sex: 50+ Male	5,022
TX_CURR_DSD	Age/Sex: 20-24 Female	1,937
TX_CURR_DSD	Age/Sex: 50+ Female	6,234
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,394
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,016
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	4,650



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive 2,96	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	5,499
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,647
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	8,726
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,901
TX_NEW_DSD	By Age/Sex: <1	18
TX_NEW_DSD	By Age/Sex: 1-9	61
TX_NEW_DSD	By Age/Sex: 10-14 Male	9
TX_NEW_DSD	By Age/Sex: 15-19 Male	24
TX_NEW_DSD	By Age/Sex: 20-24 Male	186
TX_NEW_DSD	By Age/Sex: 50+ Male	476
TX_NEW_DSD	By Age/Sex: 10-14 Female	11
TX_NEW_DSD	By Age/Sex: 15-19 Female	23
TX_NEW_DSD	By Age/Sex: 20-24 Female	112
TX_NEW_DSD	By Age/Sex: 50+ Female	
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,342
TX_NEW_DSD	Pregnancy status	251
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	162
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive 402	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39,	222



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	365
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	375
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	56,632
TX_PVLS_DSD	Denominator: Indication: Routine	56,632
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,659
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	18,673
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,941
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	34,364
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,063
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,137
TX_RET_DSD	Numerator by Status: Pregnant	177
TX_RET_DSD	Denominator by Status: Pregnant	174
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	182
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,860
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number	188



	of adults and children who are still alive and on	
	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number	
TX_RET_DSD	of adults and children who are still alive and on	3,788
	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	211
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	1,970
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	219
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	3,737
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	523
	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	480
	Male, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24,	848
	Female, Unassisted	U-10
HTS SELF DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24,	960
1110_0LLI _D0D	Male, Unassisted	300
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29,	480
HIS_SELF_DSD	Female, Unassisted	400



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	1,353
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	960
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	698
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	600
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	1,920
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	419
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	480
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	1,080
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	20,683
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	29,547
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	930
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	590
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	16,964
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	11,061
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	881



TB_PREV_DSD	By Age/Sex (Numerator): <15, Male 537	
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	11,662
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	7,602
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	36,955
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	945
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,003
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female 22,	
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	12,658
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,695
TX_TB_DSD	_DSD Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	

Implementing Mechanism Details

Mechanism ID: 18036	Mechanism Name: Cooperative Agreement UGH000710	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: African Society for Laboratory Medicine		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information			
Mechanism ID:	18036		
Mechanism Name:	Mechanism Name: Cooperative Agreement UGH000710		
Prime Partner Name:	African Society for Laboratory Medicine		
Strategic Area	Budget Code	Planned Amount	
Care	HBHC	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	CIRC	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HMBL	0	
Strategic Area	Budget Code	Planned Amount	



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18037	Mechanism Name: HRSA/I-TECH
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement



Prime Partner Name: University of Washington		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18039	TBD: Yes
REDA	CTED

Mechanism ID: 18040	Mechanism Name: WHO	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: World Health Organization		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 50,000	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 50,000			
Funding Source Funding Amount			
GHP-State	50,000		



(No data provided.)

Budget Code Information			
Mechanism ID:	18040		
Mechanism Name:	Mechanism Name: WHO		
Prime Partner Name:	World Health Organization		
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	CIRC	0	
Strategic Area	Budget Code	Planned Amount	



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	50,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)



Mechanism ID: 18088	Mechanism Name: 4Children	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Catholic Relief Services		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18126	Mechanism Name: AIDSFree	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: John Snow Inc (JSI)		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 527,200	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 527,200		
Funding Source	Funding Amount	
GHP-State	527,200	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information		
Mechanism ID: 18126		
Mechanism Name:	Mechanism Name: AIDSFree	
Prime Partner Name:	Prime Partner Name: John Snow Inc (JSI)	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	527,200
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18354	Mechanism Name: Human Resources Support
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Potentia Namibia Recruitment Consultancy	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 10,031,200	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipe	line Amount: 10,031,200	
Funding Source	Funding Amount	
GHP-State	10,031,200	

Human Resources for Health	9,066,200
Adolescent Girls and Young Women (AGYW)	280,000

Baaget Gode Information			
Mechanism ID:	18354		
Mechanism Name:	Human Resources Support		
Prime Partner Name:	Potentia Namibia Recruitment C	onsultancy	
Strategic Area	Budget Code Planned Amount		
Care	HBHC	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	736,400	
Strategic Area	Budget Code	Planned Amount	



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	311,200
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	165,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	320,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	276,150
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	280,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	7,298,100
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	644,350

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18355	Mechanism Name: Community Based Interventions	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Development Aid from People	to People, Namibia	
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 2,800,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,800,000	
Funding Source Funding Amount	
GHP-State	2,800,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information		
Mechanism ID:	18355	
Mechanism Name:	Mechanism Name: Community Based Interventions	
Prime Partner Name:	Development Aid from People to	o People, Namibia
Strategic Area	Budget Code Planned Amount	
Care	HBHC	900,900
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	100,100
Strategic Area	Budget Code	Planned Amount
Care	PDCS	100,100
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	180,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	420,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	300,300
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	198,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	600,600
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the	57,198
	minimum components during the reporting period.	



PP_PREV_DSD	Age/sex: 15-19 Male	6,765
PP_PREV_DSD	Age/sex: 20-24 Male	8,488
PP_PREV_DSD	Age/sex: 15-19 Female	9,388
PP_PREV_DSD	Age/sex: 20-24 Female	9,916
PP_PREV_DSD	Sum of Age/Sex disaggregates	34,557
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	6,062
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	2,744
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	2,288
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	3,340
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	2,859
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	1,401
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	2,417
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,530
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	72,003
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,349
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	900
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	1,798
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,349
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	450



	50+, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	299
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	1,320
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	1,849
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	221
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	1,058
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	137
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	2,641
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	100
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	2,377
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	136
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	2,114
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	51
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	2,015
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	186
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19,	1,636



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	128
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	2,651
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	251
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	2,095
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	286
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	1,447
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	123
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	1,046
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	256
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	1,050
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	149
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	1,949
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	2,847
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34,	8



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	751
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	600
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	900
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	600
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1,009
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	258
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	1,726
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	409
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	2,445
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	235
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	3,187
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	261
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39,	1,172



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	281
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	1,414
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	368
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	1,175
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	487
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	2,134
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	145
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	135
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	794
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	221
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	2,114
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	388
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	4,488
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	2,114
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	152
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39,	794



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	3,698
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	1,055
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	315
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	289
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	511
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	578
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	289
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	816
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	578
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	420
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	362
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	723
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	1,157
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	252
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	289
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male,	651



	Unassisted	
--	------------	--

Implementing Mechanism Details

Mechanism ID: 18356	Mechanism Name: Technical Assistance to provide High Quality VMMC	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: JHPIEGO		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 2,245,648	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pip	eline Amount: 2,245,648		
Funding Source Funding Amount			
GHP-State	2,245,648		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	Technical Assistance to provide High Quality VMMC	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	2,245,648
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	11,659
VMMC_CIRC_DSD	By Age: 15-19	4,913
VMMC_CIRC_DSD	By Age: 20-24	3,613
VMMC_CIRC_DSD	By Age: 25-29	3,133
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	8,526
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	11,659
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	69
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,915
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	1,537



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	875
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	504

Implementing Mechanism Details

Mechanism ID: 18357	Mechanism Name: Expansion of HIV/AIDS, STI & TB Laboratory Activities	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Namibia Institute of Pathology		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,138,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,138,000		
Funding Source Funding Amount		
GHP-State	1,138,000	

Cross-Cutting Budget Attribution(s)

Adolescent Girls and Young Women (AGYW) 50,00	00

Mechanism ID:	18357	
Mechanism Name:	Expansion of HIV/AIDS, STI & TB Laboratory Activities	
Prime Partner Name:	Namibia Institute of Pathology	
Strategic Area	Budget Code	Planned Amount



Care	НВНС	200,000
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	400,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	200,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	50,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	288,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18358	Mechanism Name: EGPAF	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

(No data provided.)

Budget Code information		
Mechanism Name	chanism ID: 18358 nism Name: EGPAF ther Name: Elizabeth Glaser Pediatric AIDS Foundation	
Fillie Faither Name.	Elizabeth Glaser Fediatric AIDS	Foundation
Strategic Area	Budget Code	Planned Amount
Care	НВНС	o
Strategic Area	Budget Code	Planned Amount
Care	HKID	o
Strategic Area	Budget Code	Planned Amount
Care	HVTB	o
Strategic Area	Budget Code	Planned Amount
Care	PDCS	o
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	o
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18359	Mechanism Name: UNAIDS	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 50,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 50,000		
Funding Source Funding Amount		
GHP-State	50,000	

Cross-Cutting Budget Attribution(s)

(No data provided.)

24490.0040.1110.1114.1011		
Mechanism ID:	18359	
Mechanism Name:	UNAIDS	
Prime Partner Name:	UNAIDS - Joint United Nations Programme on HIV/AIDS	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	30,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	20,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18360	Mechanism Name: Quality Improvement and Capacity for Impact Project (QICIP)	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: Health Research Inc./New York State Department of Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 200,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 200,000		
Funding Source	Funding Amount	



GHP-State	200,000	

(No data provided.)

Budget Code Information		
Mechanism ID:	18360	
Mechanism Name:	Quality Improvement and Capacity for Impact Project (QICIP)	
Prime Partner Name:	Health Research Inc./New York State Department of Health	
Strategic Area	Budget Code	Planned Amount
Care	нвнс	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	200,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

inpromonting incontained betain		
Mechanism ID: 18362	Mechanism Name: Association of Public Health laboratories (APHL)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Association of Public Health Laboratories		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

	18362 Association of Public Health lab Association of Public Health La	· · ·
Strategic Area	Budget Code Planned Amount	
Care	НВНС	
Strategic Area	Budget Code Planned Amount	



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18400	TBD: Yes
REDACTED	

Mechanism ID: 18401	Mechanism Name: Global Health Supply Chain-Procurement Supply Management
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Pr	ogram
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 902,894	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 902,894		
Funding Source Funding Amount		
GHP-State	902,894	

(No data provided.)

Buuget Code Illioi Illation		
Mechanism ID: Mechanism Name:	18401 Global Health Supply Chain-Procurement Supply Management	
Prime Partner Name:	Global Health Supply Chain Pro	gram
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	441,490
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	461,404
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18402	TBD: Yes
REDA	CTED

Implementing Mechanism Details

Mechanism ID: 18404	Mechanism Name: Project SOAR	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Population Council		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source	Funding Amount		

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information		
Mechanism ID:	18404	
Mechanism Name:	e: Project SOAR	
Prime Partner Name:	Population Council	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0



Stratonia Araa	Budget Code	Planned Amount
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18420	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 18430	Mechanism Name: CDC Namibia	
Funding Agency: HHS/CDC	Procurement Type: USG Core	
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source	Funding Amount		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	U.S. Department of Health and Human Services/Centers for	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18608	Mechanism Name: Technical Support to PEPFAR Programs in Southern Africa	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Baylor University, College of Medicine		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 167,391	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 167,391			
Funding Source	Funding Amount		
GHP-State	167,391		



(No data provided.)

Budget Code Information		
Mechanism ID:	18608	
	: Technical Support to PEPFAR Programs in Southern Africa : Baylor University, College of Medicine	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	167,391
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)



Mechanism ID: 18611	Mechanism Name: Clinical and Laboratory Standards Institute (CLSI)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Clinical and Laboratory Standards Institute		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
BD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

(No data provided.)

	18611 Clinical and Laboratory Standards Institute (CLSI) Clinical and Laboratory Standards Institute	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18612	Mechanism Name: Demographic and Health Surveys Program	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: ICF Macro		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information		
Mechanism ID:	18612	
Mechanism Name: Demographic and Health Surveys Program		
Prime Partner Name:	ICF Macro	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18658	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 70228	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70229	Mechanism Name: [Placeholder - 70229 Namibia HHS/CDC]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Daagot Godo III of III die			
	Mechanism ID:	70229	
	Mechanism Name:	[Placeholder - 70229 Namibia HHS/CDC]	
	Prime Partner Name:	[Placeholder]	
	Strategic Area	Budget Code	Planned Amount



Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70230	TBD: Yes
REDA	CTED

Mechanism ID: 70231	Mechanism Name: [Placeholder - 70231 Namibia HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

3		
Mechanism ID: 70231		
Mechanism Name:	[Placeholder - 70231 Namibia HHS/CDC]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

implementing incondition betails		
Mechanism ID: 70232	Mechanism Name: [Placeholder - 70232 Namibia HHS/CDC]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Mechanism ID: 70232		
Mechanism Name:	: [Placeholder - 70232 Namibia HHS/CDC]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70233	Mechanism Name: [Placeholder - 70233 Namibia HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes



Global Fund / Multilateral Engagement: N	/A	
G2G: No	Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Baaget Gode Information		
Mechanism ID:	70233	
Mechanism Name:	[Placeholder - 70233 Namibia HHS/CDC]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70234	Mechanism Name: [Placeholder - 70234 Namibia HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	70234	



Mechanism Name: Prime Partner Name:	-	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70235	Mechanism Name: [Placeholder - 70235 Namibia HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Budget Code information		
Mechanism ID: Mechanism Name: Prime Partner Name:	[Placeholder - 70235 Namibia HHS/CDC]	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

implementing meenanism betans		
Mechanism ID: 70236	Mechanism Name: [Placeholder - 70236 Namibia HHS/CDC]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: CENTRE FOR SUPPORTING COMMUNITY DEVELOPMENT INITIATIVES		
Agreement Start Date: Redacted Agreement End Date: Redacted		
BD: No New Mechanism: Yes		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Baagot Godo information		
Mechanism ID:	70236	



Mechanism Name: [Placeholder - 70236 Namibia HHS/CDC]			
Prime Partner Name:	e: CENTRE FOR SUPPORTING COMMUNITY DEVELOPMENT		
	INITIATIVES		
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	CIRC	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HMBL	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HMIN	0	
Strategic Area	Budget Code	Planned Amount	



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70237	Mechanism Name: [Placeholder - 70237 Namibia HHS/CDC]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	: [Placeholder - 70237 Namibia HHS/CDC]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

implementing incondition betains		
Mechanism ID: 70238	Mechanism Name: [Placeholder - 70238 Namib HHS/CDC]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Mechanism ID: 70238		
	e: [Placeholder - 70238 Namibia HHS/CDC]	
Prime Partner Name:	[Placeholder]	1
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70239	Mechanism Name: [Placeholder - 70239 Namibia HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes



Global Fund / Multilateral Engagement: N/A			
S2G: No Managing Agency:			
Total All Funding Sources: 0 Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source Funding Amount			

(No data provided.)

Zaagot Coao iiii oi iii alion		
Mechanism ID: 70239		
Mechanism Name:	[Placeholder - 70239 Namibia HHS/CDC]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70240	Mechanism Name: [Placeholder - 70240 Namibia HHS/CDC]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: Yes		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	70240



Mechanism Name: Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	НУТВ	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70241	Mechanism Name: [Placeholder - 70241 Namibia HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied	Pipeline Amount: 0
Funding Source	Funding Amount

(No data provided.)

Budget Code information		
Mechanism ID: Mechanism Name: Prime Partner Name:	[Placeholder - 70241 Namibia HHS/CDC]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70242	Mechanism Name: [Placeholder - 70242 Namibia HHS/HRSA]	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	70242	
Mechanism Name:	[Placeholder - 70242 Namibia HHS/HRSA]	
Prime Partner Name:	[Placeholder]	



Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70243	Mechanism Name: [Placeholder - 70243 Namibia HHS/HRSA]
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Budget Code information		
Mechanism ID: Mechanism Name: Prime Partner Name:	[Placeholder - 70243 Namibia HHS/HRSA]	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	o	

(No data provided.)

Implementing Mechanism Details

implementing mechanism betans		
Mechanism ID: 70244	Mechanism Name: [Placeholder - 70244 Namibia HHS/HRSA]	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	70244	
Mechanism Name:	[Placeholder - 70244 Namibia HHS/HRSA]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount



Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70247	TBD: Yes
REDA	CTED

Implementing Mechanism Details

Mechanism ID: 70248	TBD: Yes
REDA	CTED



Mechanism ID: 70249	Mechanism Name: Global Health Supply Chain – TO1	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Chemonics. Inc		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Baaget Gode Information		
Mechanism ID:	70249	
Mechanism Name:	Global Health Supply Chain – TO1	
Prime Partner Name:	Chemonics. Inc	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	O



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	495,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	70,599
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,114,745
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	75,449

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70250	Mechanism Name: Global Health Supply Chain – Rapid Test Kits	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Remote Medical International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information		
Mechanism ID: 70250		
Mechanism Name: Global Health Supply Chain – Rapid Test Kits		
Prime Partner Name: Remote Medical International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70251	Mechanism Name: [Placeholder - 70251 Namibia USAID]
Funding Agency: USAID	Procurement Type: Grant



Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: Yes		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Mechanism ID: 70251 Mechanism Name: [Placeholder - 70251 Namibia USAID] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

mplementing meenament betane		
Mechanism ID: 70252	Mechanism Name: [Placeholder - 70252 Namibia USAID]	
Funding Agency: USAID	Procurement Type: Grant	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	No New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information		
Mechanism ID: 70252 Mechanism Name: [Placeholder - 70252 Namibia USAID] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70253	Mechanism Name: [Placeholder - 70253 Namibia USAID]
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 0				
Funding Source Funding Amount				

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	[Placeholder - 70253 Namibia USAID]				
Strategic Area	Budget Code	Planned Amount			
Care	HBHC	0			
Strategic Area	Budget Code	Planned Amount			
Care	HKID	0			
Strategic Area	Budget Code	Planned Amount			
Care	HVTB	0			
Strategic Area	Budget Code	Planned Amount			
Care	PDCS	0			
Strategic Area	Budget Code	Planned Amount			



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70511	TBD: Yes
REDA	CTED



Agency Information - Costs of Doing Business

U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		232,893		232,893	0	232,893
ICASS		20,873		20,873	527,632	548,505
Management Meetings/Profes sional Development		0		0	149,185	149,185
Non-ICASS Administrative Costs		0		0	861,706	861,706
Non-ICASS Motor Vehicles		0		0	95,000	95,000
Staff Program Travel		0	0	0	331,976	331,976
USG Staff Salaries and Benefits - Internationally Recruited		1,317,174	0	1,317,174	0	1,317,174
USG Staff Salaries and Benefits - Locally Recruited		1,423,892	0	1,423,892	0	1,423,892



Total	0 2,994,832	. 0	2,994,832	1,965,499	4,960,331
-------	-------------	-----	-----------	-----------	-----------

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		72,797		72,797	0	72,797
Computers/IT Services		60,000		60,000	0	60,000
ICASS		859,000		859,000	0	859,000
Institutional Contractors		2,140,616		2,140,616	0	2,140,616
Management Meetings/Profes sional Development		61,000		61,000	0	61,000
Non-ICASS Administrative Costs		589,906		589,906	0	589,906
Non-ICASS Motor Vehicles		95,000		95,000	0	95,000
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		524,810		524,810	0	524,810
USG Staff Salaries and Benefits -	1,487,500	1,392,646		2,880,146	0	2,880,146



Internationally						
Recruited						
USG Staff						
Salaries and						
Benefits -		1,821,811		1,821,811	0	1,821,811
Locally						
Recruited						
Total	1,487,500	7,617,586	0	9,105,086	0	9,105,086

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		86,000		86,000	0	86,000
Management Meetings/Profes sional Development		0		0	28,000	28,000
Non-ICASS Administrative Costs		0		0	191,000	191,000
Peace Corps Volunteer Costs		0		0	15,000	15,000
Staff Program Travel		0		0	56,000	56,000
USG Staff Salaries and Benefits - Locally Recruited		90,204		90,204	115,609	205,813



Total	0 176	6,204 0	176,204	405,609	581,813
-------	-------	---------	---------	---------	---------

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Institutional Contractors				0	0	0
Non-ICASS Administrative Costs		312,944		312,944	0	312,944
Peace Corps Volunteer Costs		388,710		388,710	261,047	649,757
Staff Program Travel		82,866		82,866	0	82,866
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits - Locally Recruited		219,227		219,227	0	219,227
Total	0	1,003,747	0	1,003,747	261,047	1,264,794